NZ739056B2 - Enhancing microbial metabolism of c5 organic carbon - Google Patents
Enhancing microbial metabolism of c5 organic carbon Download PDFInfo
- Publication number
- NZ739056B2 NZ739056B2 NZ739056A NZ73905616A NZ739056B2 NZ 739056 B2 NZ739056 B2 NZ 739056B2 NZ 739056 A NZ739056 A NZ 739056A NZ 73905616 A NZ73905616 A NZ 73905616A NZ 739056 B2 NZ739056 B2 NZ 739056B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- xylose
- nucleic acid
- acid sequence
- optionally
- isomerase
- Prior art date
Links
- 229910052799 carbon Inorganic materials 0.000 title abstract description 22
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title abstract description 21
- 230000036740 Metabolism Effects 0.000 title description 7
- 230000004060 metabolic process Effects 0.000 title description 7
- 230000035786 metabolism Effects 0.000 title description 7
- 230000002708 enhancing Effects 0.000 title description 4
- 230000000813 microbial Effects 0.000 title description 2
- SRBFZHDQGSBBOR-SQOUGZDYSA-N Xylose Natural products O[C@@H]1CO[C@@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-SQOUGZDYSA-N 0.000 claims abstract description 270
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 163
- 229960003487 Xylose Drugs 0.000 claims abstract description 135
- 244000005700 microbiome Species 0.000 claims abstract description 112
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 85
- 229920001850 Nucleic acid sequence Polymers 0.000 claims abstract description 83
- 108020000244 Xylose isomerases Proteins 0.000 claims abstract description 77
- 102100000499 XYLB Human genes 0.000 claims abstract description 55
- 108091022071 xylulokinase Proteins 0.000 claims abstract description 55
- 239000002253 acid Substances 0.000 claims description 32
- 241000233675 Thraustochytrium Species 0.000 claims description 29
- 102000004195 Isomerases Human genes 0.000 claims description 27
- 108090000769 Isomerases Proteins 0.000 claims description 27
- 102000030951 Phosphotransferases Human genes 0.000 claims description 13
- 108091000081 Phosphotransferases Proteins 0.000 claims description 13
- 210000004027 cells Anatomy 0.000 description 85
- 239000002609 media Substances 0.000 description 52
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 30
- 229960002675 Xylitol Drugs 0.000 description 30
- 239000000811 xylitol Substances 0.000 description 30
- 235000010447 xylitol Nutrition 0.000 description 30
- 239000003550 marker Substances 0.000 description 29
- 239000007787 solid Substances 0.000 description 29
- 229960001031 Glucose Drugs 0.000 description 25
- 241001467333 Thraustochytriaceae Species 0.000 description 25
- 230000000694 effects Effects 0.000 description 25
- 229920001184 polypeptide Polymers 0.000 description 25
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 25
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 24
- 239000008103 glucose Substances 0.000 description 24
- 101700051037 XYLB Proteins 0.000 description 23
- 239000000203 mixture Substances 0.000 description 23
- 101700075090 XDH Proteins 0.000 description 22
- 150000002632 lipids Chemical class 0.000 description 22
- 101710038554 xynBS9 Proteins 0.000 description 22
- 239000003921 oil Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 239000002028 Biomass Substances 0.000 description 20
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 19
- 239000012528 membrane Substances 0.000 description 18
- 230000001965 increased Effects 0.000 description 17
- 241000588724 Escherichia coli Species 0.000 description 16
- -1 glucose Chemical class 0.000 description 16
- 230000037361 pathway Effects 0.000 description 16
- 235000002639 sodium chloride Nutrition 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- 238000000855 fermentation Methods 0.000 description 15
- 230000004151 fermentation Effects 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 101710040885 TWIST1 Proteins 0.000 description 14
- 230000003115 biocidal Effects 0.000 description 14
- 230000012010 growth Effects 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 235000000346 sugar Nutrition 0.000 description 14
- 230000001131 transforming Effects 0.000 description 14
- 102000000132 Alpha tubulin Human genes 0.000 description 13
- 108050008484 Alpha tubulin Proteins 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 230000004127 xylose metabolism Effects 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 238000002105 Southern blotting Methods 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 238000003780 insertion Methods 0.000 description 11
- ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 10
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 102000004243 Tubulin Human genes 0.000 description 8
- 108090000704 Tubulin Proteins 0.000 description 8
- 238000004166 bioassay Methods 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 230000002068 genetic Effects 0.000 description 8
- 229920000023 polynucleotide Polymers 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- DTOSIQBPPRVQHS-PDBXOOCHSA-N α-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000010432 diamond Substances 0.000 description 7
- 239000001963 growth media Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000001105 regulatory Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 108010058076 D-Xylulose Reductase Proteins 0.000 description 6
- 101700012085 GRE3 Proteins 0.000 description 6
- OYHQOLUKZRVURQ-IXWMQOLASA-N Linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 6
- 239000004677 Nylon Substances 0.000 description 6
- 102100013658 SORD Human genes 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 229920001778 nylon Polymers 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 108020004999 Messenger RNA Proteins 0.000 description 5
- 241000233671 Schizochytrium Species 0.000 description 5
- VBJHPXDIVMXHJU-UHFFFAOYSA-N Zeocin Chemical compound N=1C(C=2SC=C(N=2)C(=O)NCCCCN=C(N)N)CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1[N]C=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C VBJHPXDIVMXHJU-UHFFFAOYSA-N 0.000 description 5
- 108010084455 Zeocin Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000001186 cumulative Effects 0.000 description 5
- 230000003247 decreasing Effects 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 5
- 235000003642 hunger Nutrition 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 229920002106 messenger RNA Polymers 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 238000009928 pasteurization Methods 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 230000037351 starvation Effects 0.000 description 5
- YEKFYCQGYMVFKR-MBFZXKRTSA-N (2E,4E,6E,8E,10E)-docosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C(O)=O YEKFYCQGYMVFKR-MBFZXKRTSA-N 0.000 description 4
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 4
- 229960005135 Eicosapentaenoic Acid Drugs 0.000 description 4
- JAZBEHYOTPTENJ-JLNKQSITSA-N Eicosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 4
- 241000229754 Iva xanthiifolia Species 0.000 description 4
- 229960004488 Linolenic Acid Drugs 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 235000011148 calcium chloride Nutrition 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 3
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 3
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 3
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 3
- 229940114079 Arachidonic Acid Drugs 0.000 description 3
- YZXBAPSDXZZRGB-DOFZRALJSA-N Arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 3
- GVPFVAHMJGGAJG-UHFFFAOYSA-L Cobalt(II) chloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 3
- 229920001405 Coding region Polymers 0.000 description 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N Docosahexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 3
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N Palmitic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- SECPZKHBENQXJG-FPLPWBNLSA-N Palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 3
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 102000004965 antibodies Human genes 0.000 description 3
- 108090001123 antibodies Proteins 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 230000037348 biosynthesis Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000001413 cellular Effects 0.000 description 3
- 229960004363 doconexent Drugs 0.000 description 3
- 229940090949 docosahexaenoic acid Drugs 0.000 description 3
- 239000000446 fuel Substances 0.000 description 3
- 229940044550 gamma-Linolenic Acid Drugs 0.000 description 3
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 3
- 229960002733 gamolenic acid Drugs 0.000 description 3
- 230000000102 heterotrophic Effects 0.000 description 3
- 229940079866 intestinal antibiotics Drugs 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- 229960004232 linoleic acid Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 3
- 230000000243 photosynthetic Effects 0.000 description 3
- 235000003441 saturated fatty acids Nutrition 0.000 description 3
- 150000004671 saturated fatty acids Chemical class 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VZCCETWTMQHEPK-QNEBEIHSSA-N γ-Linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 3
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical class CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 241000238424 Crustacea Species 0.000 description 2
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 2
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 2
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Destomysin Chemical compound OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 229960003082 Galactose Drugs 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 229940097277 Hygromycin B Drugs 0.000 description 2
- 101700029869 IL3RA Proteins 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K Iron(III) chloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 2
- 229920001320 Leader sequence (mRNA) Polymers 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L MANGANESE CHLORIDE Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M Monopotassium phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 229920002224 Peptide nucleic acid Polymers 0.000 description 2
- 241000193632 Piromyces sp. Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001914 Ribonucleotide Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229960000344 Thiamine hydrochloride Drugs 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 241001491678 Ulkenia Species 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 241000209149 Zea Species 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000001580 bacterial Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000001851 biosynthetic Effects 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 229960002713 calcium chloride Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000024881 catalytic activity Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000002759 chromosomal Effects 0.000 description 2
- 125000003346 cobalamin group Chemical group 0.000 description 2
- 230000000295 complement Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 235000005824 corn Nutrition 0.000 description 2
- 230000002596 correlated Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000006052 feed supplement Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium(0) Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 235000002867 manganese chloride Nutrition 0.000 description 2
- 229940099607 manganese chloride Drugs 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 108091007521 restriction endonucleases Proteins 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 230000003248 secreting Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229960003339 sodium phosphate Drugs 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 2
- 239000011747 thiamine hydrochloride Substances 0.000 description 2
- 238000002700 transcriptomic Methods 0.000 description 2
- 239000011778 trisodium citrate Substances 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 229930003231 vitamins Natural products 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-Aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- WHJKCPTVEYZNOG-UHFFFAOYSA-N 6-(hydroxymethyl)-5-methoxy-2-[4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane-3,4-diol Chemical compound COCC1OC(OC)C(OC)C(OC)C1OC1C(O)C(O)C(OC)C(CO)O1 WHJKCPTVEYZNOG-UHFFFAOYSA-N 0.000 description 1
- 108060000492 ARG7 Proteins 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N Actinospectacin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- DVARTQFDIMZBAA-UHFFFAOYSA-O Ammonium nitrate Chemical compound [NH4+].[O-][N+]([O-])=O DVARTQFDIMZBAA-UHFFFAOYSA-O 0.000 description 1
- ZRIUUUJAJJNDSS-UHFFFAOYSA-N Ammonium phosphates Chemical compound [NH4+].[NH4+].[NH4+].[O-]P([O-])([O-])=O ZRIUUUJAJJNDSS-UHFFFAOYSA-N 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 241000003610 Aplanochytrium Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000009042 Argininosuccinate lyases Human genes 0.000 description 1
- 108091000035 Argininosuccinate lyases Proteins 0.000 description 1
- 241000228257 Aspergillus sp. Species 0.000 description 1
- 101710027713 At5g17010 Proteins 0.000 description 1
- 101710027711 At5g59250 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-M COP([O-])=O Chemical class COP([O-])=O QCMYYKRYFNMIEC-UHFFFAOYSA-M 0.000 description 1
- 101700021600 CRY1 Proteins 0.000 description 1
- 229960005069 Calcium Drugs 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 229940041514 Candida albicans extract Drugs 0.000 description 1
- 229960005091 Chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N Chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 229920002676 Complementary DNA Polymers 0.000 description 1
- 229960000355 Copper Sulfate Drugs 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L Copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-Galacturonic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- 101700050373 DTX49 Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241001462977 Elina Species 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N Emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- 229940009714 Erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N Erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 229960000304 Folic Acid Drugs 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229960002737 Fructose Drugs 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229960002442 Glucosamine Drugs 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- BYSGBSNPRWKUQH-UJDJLXLFSA-N Glycogen Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)O1 BYSGBSNPRWKUQH-UJDJLXLFSA-N 0.000 description 1
- 229940096919 Glycogen Drugs 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 241000282619 Hylobates lar Species 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L Iron(II) chloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N Lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229940045184 Malt extract Drugs 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N Maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 230000035633 Metabolized Effects 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 210000000214 Mouth Anatomy 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-ACETYL-D-GALACTOSAMINE Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-Acetylglucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 229950006780 N-Acetylglucosamine Drugs 0.000 description 1
- OVRNDRQMDRJTHS-OZRXBMAMSA-N N-Acetylmannosamine Chemical compound CC(=O)N[C@@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-OZRXBMAMSA-N 0.000 description 1
- 101700039615 NIC1 Proteins 0.000 description 1
- 102100011085 NIT1 Human genes 0.000 description 1
- 101700023247 NIT1 Proteins 0.000 description 1
- 101700000165 NLP2 Proteins 0.000 description 1
- 101710027788 NPEPPS Proteins 0.000 description 1
- 210000001577 Neostriatum Anatomy 0.000 description 1
- LGQLOGILCSXPEA-UHFFFAOYSA-L Nickel(II) sulfate Chemical compound [Ni+2].[O-]S([O-])(=O)=O LGQLOGILCSXPEA-UHFFFAOYSA-L 0.000 description 1
- 108090000913 Nitrate Reductases Proteins 0.000 description 1
- 108091005503 Nucleic proteins Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000235061 Pichia sp. Species 0.000 description 1
- XMXNVYPJWBTAHN-UHFFFAOYSA-N Potassium chromate Chemical compound [K+].[K+].[O-][Cr]([O-])(=O)=O XMXNVYPJWBTAHN-UHFFFAOYSA-N 0.000 description 1
- 229960004172 Pyridoxine Hydrochloride Drugs 0.000 description 1
- 206010038997 Retroviral infection Diseases 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N Ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 229960002477 Riboflavin Drugs 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- AUNGANRZJHBGPY-OUCADQQQSA-N Riboflavin Natural products OC[C@@H](O)[C@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-OUCADQQQSA-N 0.000 description 1
- 108091006418 SLC26A1 Proteins 0.000 description 1
- 241000235088 Saccharomyces sp. Species 0.000 description 1
- MCAHWIHFGHIESP-UHFFFAOYSA-N Selenous acid Chemical compound O[Se](O)=O MCAHWIHFGHIESP-UHFFFAOYSA-N 0.000 description 1
- 229940073490 Sodium Glutamate Drugs 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N Sodium molybdate Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N Sodium orthovanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N Sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 238000010793 Steam injection (oil industry) Methods 0.000 description 1
- 241000203644 Streptoalloteichus hindustanus Species 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- 241000187391 Streptomyces hygroscopicus Species 0.000 description 1
- 241000187310 Streptomyces noursei Species 0.000 description 1
- 241000187419 Streptomyces rimosus Species 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 101700011244 THI7 Proteins 0.000 description 1
- 102100012038 TIRAP Human genes 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 241001298230 Thraustochytrium sp. Species 0.000 description 1
- 229940035295 Ting Drugs 0.000 description 1
- 240000008529 Triticum aestivum Species 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- UWHZIFQPPBDJPM-FPLPWBNLSA-M Vaccenic acid Natural products CCCCCC\C=C/CCCCCCCCCC([O-])=O UWHZIFQPPBDJPM-FPLPWBNLSA-M 0.000 description 1
- 229940088594 Vitamin Drugs 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L Zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- NRAUADCLPJTGSF-ZPGVOIKOSA-N [(2R,3S,4R,5R,6R)-6-[[(3aS,7R,7aS)-7-hydroxy-4-oxo-1,3a,5,6,7,7a-hexahydroimidazo[4,5-c]pyridin-2-yl]amino]-5-[[(3S)-3,6-diaminohexanoyl]amino]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl] carbamate Chemical compound NCCC[C@H](N)CC(=O)N[C@@H]1[C@@H](O)[C@H](OC(N)=O)[C@@H](CO)O[C@H]1\N=C/1N[C@H](C(=O)NC[C@H]2O)[C@@H]2N\1 NRAUADCLPJTGSF-ZPGVOIKOSA-N 0.000 description 1
- 241000191335 [Candida] intermedia Species 0.000 description 1
- YKMOGQRKFMLWCI-UHFFFAOYSA-L [Cl-].[Ca+2].[Cl-].[Mn+2] Chemical compound [Cl-].[Ca+2].[Cl-].[Mn+2] YKMOGQRKFMLWCI-UHFFFAOYSA-L 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 101710029159 aadA Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 102000006646 aminoglycoside phosphotransferase family Human genes 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000019730 animal feed additive Nutrition 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003225 biodiesel Substances 0.000 description 1
- 239000002551 biofuel Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- NVTRPRFAWJGJAJ-UHFFFAOYSA-L calcium;2-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Ca+2].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O NVTRPRFAWJGJAJ-UHFFFAOYSA-L 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- UWHZIFQPPBDJPM-FPLPWBNLSA-N cis-vaccenic acid Chemical compound CCCCCC\C=C/CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-FPLPWBNLSA-N 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000023298 conjugation with cellular fusion Effects 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000000593 degrading Effects 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 230000001809 detectable Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- RXVWSYJTUUKTEA-CGQAXDJHSA-N maltotriose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 RXVWSYJTUUKTEA-CGQAXDJHSA-N 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 101700023501 mntA Proteins 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- LPUQAYUQRXPFSQ-UHFFFAOYSA-M monosodium glutamate Chemical compound [Na+].[O-]C(=O)C(N)CCC(O)=O LPUQAYUQRXPFSQ-UHFFFAOYSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229940053662 nickel sulfate Drugs 0.000 description 1
- 229910000363 nickel(II) sulfate Inorganic materials 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 108010041935 nourseothricin acetyltransferase Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000001938 protoplasts Anatomy 0.000 description 1
- 101700032180 psaA Proteins 0.000 description 1
- 101700029871 psaB Proteins 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229920002973 ribosomal RNA Polymers 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 101710033952 sloC Proteins 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 230000001954 sterilising Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 108010015544 streptothricin acetyltransferase Proteins 0.000 description 1
- 238000009923 sugaring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 235000019529 tetraterpenoid Nutrition 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical class [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 239000003744 tubulin modulator Substances 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 230000021037 unidirectional conjugation Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 235000021307 wheat Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- HXXFSFRBOHSIMQ-VFUOTHLCSA-N α-D-glucose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-VFUOTHLCSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/38—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Aspergillus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
- C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/10—Protozoa; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/12—Unicellular algae; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
- C12N9/92—Glucose isomerase (5.3.1.5; 5.3.1.9; 5.3.1.18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01017—Xylulokinase (2.7.1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y503/00—Intramolecular oxidoreductases (5.3)
- C12Y503/01—Intramolecular oxidoreductases (5.3) interconverting aldoses and ketoses (5.3.1)
- C12Y503/01005—Xylose isomerase (5.3.1.5)
Abstract
Provided herein are recombinant microorganisms having two or more copies of a nucleic acid sequence encoding xylose isomerase, wherein the nucleic acid encoding the xylose isomerase is an exogenous nucleic acid. Optionally, the recombinant microorganisms include at least one nucleic acid sequence encoding a xylulose kinase and/or at least one nucleic acid sequence encoding a xylose transporter. The provided recombinant microorganisms are capable of growing on xylose as a carbon source. coding a xylulose kinase and/or at least one nucleic acid sequence encoding a xylose transporter. The provided recombinant microorganisms are capable of growing on xylose as a carbon source.
Description
ENHANCING MICROBIAL METABOLISM OF C5 ORGANIC
CARBON
CROSS-REFERENCE TO D ATIONS
This application claims the benefit of priority to U.S. Provisional Application No.
62/191,983, filed July 13, 2015, and U.S. Provisional Application No. 62/354,444, filed June
24, 2016, which are incorporated by reference herein in their entireties.
BACKGROUND OF THE INVENTION
Heterotrophic tation of rganisms is an efficient way of generating
high value oil and biomass products. Under certain cultivation conditions, microorganisms
synthesize intracellular oil, which can be extracted and used to produce fuel (e.g., biodiesel,
tfuel, and the like) and ional lipids (e.g., polyunsaturated fatty acids such as DHA,
EPA, and DPA). The biomass of some microorganisms is of great ional value due to
high polyunsaturated fatty acid (PUFA) and protein content, and can be used as a nutritional
supplement for animal feed. Thraustochytrids are eukaryotic, single-cell, microorganisms
which can be used in such fermentation processes to produce lipids. Heterotrophic
fermentations with Thraustochytrids convert organic carbon provided in the growth medium
to lipids, which are harvested from the biomass at the end of the fermentation process.
However, existing microorganism fermentations use mainly ive carbohydrates, such as
glucose, as the carbon source.
BRIEF Y OF THE INVENTION
sed herein are recombinant microorganisms having two or more copies of a
nucleic acid sequence encoding xylose isomerase, wherein the nucleic acid encoding the
xylose isomerase is an exogenous nucleic acid. Optionally, the recombinant microorganisms
include at least one nucleic acid sequence encoding a xylulose kinase and/or at least one
nucleic acid sequence encoding a xylose transporter. The disclosed recombinant
microorganisms are capable of growing on xylose as a carbon source.
A first aspect provides a recombinant Thraustochytrium microorganism comprising:
a) two or more copies of a nucleic acid sequence encoding xylose isomerase, wherein
the c acid encoding xylose isomerase is an ous nucleic acid;
17746603_1 (GHMatters) P107943.NZ 1 04/06/2021
b) two or more copies of a nucleic acid sequence ng a xylulose kinase; and
c) at least one nucleic acid ce encoding a xylose transporter,
wherein the isomerase, kinase and transporter are integrated into the genome of the
Thraustochytrium rganism.
A second aspect provides a method of making a recombinant xylose-metabolizing
Thraustochytrium microorganism comprising:
i. transforming the tochytrium microorganism with one or more nucleic acid
constructs comprising a c acid sequence encoding a xylose isomerase, a nucleic acid
sequence encoding a xylulose kinase and a nucleic acid sequence encoding a xylose
transporter; and
ii. isolating the Thraustochytrium microorganism comprising at least two or more
copies of the nucleic acid sequences encoding the xylose isomerase, at least two copies of the
nucleic acid ce encoding the xylulose kinase and at least one copy of the nucleic acid
sequence encoding the xylose transporter,
wherein the isomerase, kinase and transporter are integrated into the genome of the
Thraustochytrium microorganism.
A third aspect provides a method of producing oil comprising:
culturing the recombinant Thraustochytrium rganism of the first aspect in a culture
medium to produce the oil, wherein the microorganism grows on xylose as the sole carbon
source.
17746603_1 (GHMatters) P107943.NZ 1a 04/06/2021
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a tic of the xylose metabolism pathway.
Figure 2 is a graph showing expression of xylose isomerase in WT ONC-T18
during cycles of glucose starvation.
Figure 3 is a graph showing expression of the putative xylulose kinase in WT ONCT18
during cycles of glucose starvation.
Figure 4 is a schematic showing an alpha-tubulin ble-isomerase d construct.
Figure 5 is a schematic showing an alpha-tubulin xylB plasmid construct.
Figure 6 is a schematic showing a nucleic acid construct having an alpha-tubulin
promoter a ble sequence a 2A sequence an xylose isomerase sequence and an alpha-tubulin
ator.
Figure 7 is an image of a Southern blot to probe the xylose isomerase His-tagged
gene within recombinant ONC-T18 strains “6” and “16”.
Figure 8 is a graph showing the qPCR determination of the number of xylose
isomerase His-tagged gene insertions in recombinant ONC-T18 strains.
Figure 9 is an image of a Southern blot to probe the xylB gene within recombinant
8 strains containing both xylose isomerase and xylulose kinase referred to in the
graph as “7-3” and “7-7”.
Figure 10 is a graph of qPCR determination of the number of xylB gene insertions in
recombinant 7-3 and 7-7 ONC-T18 strains.
Figure 11 is a graph showing the expression of the xylose ase gene transcript
in recombinant ONC-T18 strains “6” and “16.”
Figure 12 is a graph showing the in vitro xylose isomerase activity in Wt ONC-T18
and inant ONC-T18 strains “6” and “16.”
Figure 13 is a graph showing the combined xylose isomerase and se kinase
activity in vitro of recombinant ONC-T18 strain “16” encoding only xylose isomerase and
recombinant 8 strains “7-3” and “7-7” encoding xylose isomerase and xylulose
kinase.
Figures 14A and 14B are graphs showing xylose uptake improvement and
decreased xylitol production in recombinant 8 strain “16” (squares). The Wild Type
(WT) strain is represented by ds.
Figures 15A and 15B are graphs showing xylose usage improvement and decreased
xylitol production in recombinant 8 strain “16” (squares) and recombinant ONC-T18
17746603_1 (GHMatters) P107943.NZ 2 04/06/2021
strains “7-3” (triangles) and “7-7” (asterisks). The Wild Type (WT) strain is represented by
Figure 16 is a graph g accumulation of xylitol during a glucose:xylose
fermentation with recombinant ONC-T18 strain “16” and recombinant ONC-T18 strain “7-
Figure 17 is a schematic of different versions of the ucts used for
transformation of ONC-T18.
Figure 18 is a graph showing the ent of the xylB sequence from E. coli (SEQ
ID NO:20) with the codon optimized version of E. coli xylB (SEQ ID NO:5).
Figures 19A, 19B, and 19C are graphs g xylose usage (Fig. 19A), glucose
usage (Fig. 19B) and percent xylitol made (Fig. 19C) in strains comprising xylose isomerase,
xylulose kinase and the sugar transporter Gxs1. WT is wild-type; IsoHis XylB “7-7”
contains the xylose isomerase and xylB sequences, 36-2, 36-9 and 36-16 are ormants
containing Gxs1, xylose isomerase and the xylB sequences (xylulose ).
Figures 20A and 20B are graphs showing the impact of temperature incubation on
the activity of isomerase from T18 (Figure 20A) and E. coli (Figures 20B) with xylose
(diamond) and xylulose (square).
Figures 21A and 21B are graphs g dose dependency of isomerase from T18
(Figure 21A) and E. coli (Figure 21B) with xylose (diamond) and xylulose (square).
Figures 22A and 22B are graphs showing xylose use (Figure 22A) and decreased
l production (Figure 22B) in a T18B strain engineered with xylose isomerases (“16”
(squares), “B” (x), and “6” (crosses)). s 22C (xylose) and 22D (xylitol production)
show the same data expressed relative to wild type (diamonds) at 4 (gray) and 7 (black) days.
Figures 23A and 23B are graphs showing xylose use and decreased xylitol
tion in a T18B strain ered with a xylose isomerase “16” (squares) and strains
engineered to express a xylose isomerase and xylulose kinase “7-7” (x) and “7-3” (triangles).
Figures 23C (xylose) and 23D (xylitol production) show the same data relative to wild type
(diamonds) at 9 (gray) and 11 (black) days.
Figure 24 is a graph showing improved xylose usage and decreased xylitol
production in a T18B strain engineered to express a xylose isomerase and xylulose kinase “7-
7” in fermentation. The wild type strain is represented by diamonds and the dotted line and
the strain “7-7” is represented by circles.
Figure 25 is a schematic showing α-tubulin aspTx-neo and α-tubulin gxs1-neo
constructs.
03_1 (GHMatters) P107943.NZ 3 04/06/2021
Figure 26A is an image of a Southern blot to probe the Gxs1 gene within “7-7”
T18B strains engineered with the xylose transporter Gxs1. Figure 26B is an image of a
Southern blot to probe the AspTx gene within “7-7” T18B strains engineered with the xylose
transporter AspTx.
Figures 27A is a graph showing the use of xylose in T18 strains engineered with a
xylose isomerase, a se kinase and either the Gxs1 transporter (triangles) or AspTx
transporter (circles). Strain “7-7” is represented by diamonds. Figure 27B is a bar graph of
the ratio of xylitol production versus xylose use for each of the 3 modified strains. Figure
27C is a bar graph showing xylose use relative to strain “7-7.” Figures 27D is a bar graph
showing xylitol production made relative to strain “7-7.”
Figures 28 is a graph showing growth of wild type (WT) (diamonds), isohis strain
“16” (squares), strain “7-7” (x), and transporter strains Gxs1 (asterisks) and AspTx (triangles)
in media containing xylose as sole carbon source.
Figure 29A is a graph g remaining e in alternative feedstock containing
e and xylose during growth of WT (squares), strain “7-7” (triangles), and transporter
strains Gxs1 (asterisks) and AspTx (crosses). Figure 29B is a graph showing xylose
remaining and xylitol produced over time when WT (squares) strain “7-7” (triangles) and
transporter s Gxs1 (asterisks) and AspTx (crosses) are grown on alternative feedstock
containing glucose and xylose.
DETAILED DESCRIPTION OF THE INVENTION
Microorganisms such as Thraustochytrids encode genes required for the metabolism
of xylose. However, the microorganism’s innate metabolic pathways produce a large amount
of the sugar alcohol, xylitol, which is secreted and potentially hinders growth of the
microorganisms (see Figure 14, WT). Furthermore, carbon atoms sequestered into xylitol are
atoms that are diverted away from the target product in this process, namely, lipid tion.
In nature, two xylose metabolism pathways exist, the xylose reductase/xylitol dehydrogenase
pathway and the xylose isomerase/xylulose kinase y e 1). Thraustochytrids
have genes that encode proteins active in both pathways; however, the former pathway
appears to be dominant as evidenced by a up of xylitol when grown in a xylose
medium. In other organisms, the build-up of xylitol has been shown to be due to a redox cofactor
imbalance ed for xylose reductase/xylitol dehydrogenase y. Since the
isomerase/kinase pathway does not depend on redox co-factors, xpression of the
isomerase gene removes co-factor dependence in the conversion of xylose to xylulose. As
shown herein, transcriptomic s with ONC-T18 showed that its xylose isomerase and
17746603_1 (GHMatters) P107943.NZ 4 04/06/2021
putative xylulose kinase genes are mostly expressed during glucose tion (Figure 2 and
Figure 3); whereas, the putatively identified genes encoding for the xylose reductase and
xylitol dehydrogenase are constitutively expressed. To se the expression of the
ase and kinase hout all growth stages, microorganisms were engineered to
include ONC-T18 isomerase gene and an E. coli xylulose kinase gene (xylB) such that they
are under the control of the constitutively expressed promoter and terminator, e.g., an αtubulin
promoter and terminator. Optionally, the genes can be under the control of a
inducible promoter and/or terminator.
The provided recombinant microorganisms demonstrate a level of control of the
amount of expression of a gene of st via the number of integrated transgene copies. As
shown in the examples below, a recombinant ONC-T18 strain (Iso-His #16) harbouring eight
(8) transgene copies demonstrates higher levels of xylose ase transcript sion,
enzyme activity and xylose metabolism than a strain harbouring a single copy of the
transgene (Iso-His #6). When Iso-His #16 was further ed to incorporate the xylB gene,
a similar phenomenon is observed. Multiple copies of the xylB gene conferred greater
enzyme ty and xylose metabolism tivity compared to single insertions. Thus,
unexpectedly, it was not only necessary to recreate a xylose metabolism pathway, but to do
so with multiple copies of the necessary transgenes. It was not pated that the
Thraustrochytrid genome could accommodate multiple transgene copies and remain viable;
therefore, it was not expected to observe such variability in expression levels amongst
ormant strains. However, as provided , recombinant microorganisms can be
produced that allow for controlled expression levels of transgenes indirectly by ing
among transformant strains that possess a transgene copy number “tailored” to a particular
expression level optimized for the metabolic engineering of a ular pathway, e.g., the
xylose pathway.
Provided herein are nucleic acids encoding one or more genes involved in xylose
metabolism. The present application provides recombinant microorganisms, methods for
making the microorganisms, and methods for producing oil using the microorganisms that are
capable of metabolizing xylose. Specifically, provided herein are nucleic acids and
polypeptides encoding xylose isomerase, xylulose kinase and xylose transporters for
modifying microorganisms to be capable of lizing xylose and/or growing on xylose as
the sole carbon . Thus, provided are nucleic acids encoding a xylose isomerase. The
nucleic acid sequences can be endogenous or heterologous to the microorganism. Exemplary
nucleic acids sequences of xylose isomerases include, but are not limited to, those from
17746603_1 (GHMatters) P107943.NZ 5 04/06/2021
Piromyces sp., Streptococcus sp., and Thraustochytrids. For example, exemplary nucleic
acid sequences encoding xylose isomerases include, but are not d to, SEQ ID NO:2 and
SEQ ID NO:15; and exemplary polypeptide sequences of xylose isomerase include, but are
not limited to, SEQ ID NO:16. Exemplary nucleic acids sequences of se kinases
include, but are not limited to, those from E. coli, Piromyces sp., Saccharomyces sp., and
Pichia sp. For example, exemplary c acid sequences encoding xylulose kinases
include, but are not limited to, SEQ ID NO:5, SEQ ID NO:17, SEQ ID NO:18, SEQ ID
NO:19 and SEQ ID NO:20. Exemplary nucleic acid ces encoding sugar transporters,
e.g., xylose transporters, include, but are not limited to, those from Aspergillus sp., Gfx1,
Gxs1 and Sut1. For example, ary nucleic acid sequences encoding xylose transporters
include, but are not limited to, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, and SEQ ID
NO:24.
Nucleic acid, as used herein, refers to deoxyribonucleotides or cleotides and
polymers and complements thereof. The term includes deoxyribonucleotides or
ribonucleotides in either single- or double-stranded form. The term encompasses c
acids containing known nucleotide analogs or modified backbone residues or es, which
are synthetic, naturally occurring, and non-naturally occurring, which have similar binding
properties as the reference nucleic acid, and which are metabolized in a manner similar to the
reference nucleotides. Examples of such analogs include, without limitation,
phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-
O-methyl ribonucleotides, peptide-nucleic acids (PNAs). Unless otherwise indicated,
conservatively modified variants of nucleic acid ces (e.g., degenerate codon
substitutions) and complementary ces can be used in place of a particular nucleic acid
sequence recited herein. Specifically, degenerate codon substitutions may be achieved by
generating sequences in which the third position of one or more selected (or all) codons is
substituted with mixed-base and/or nosine residues (Batzer et al., Nucleic Acid Res.
19:5081 (1991); a et al., J. Biol. Chem. 260:2605-2608 (1985); Rossolini et al., Mol.
Cell. Probes 8:91-98 (1994)). The term nucleic acid is used interchangeably with gene,
cDNA, mRNA, oligonucleotide, and polynucleotide.
A nucleic acid is operably linked when it is placed into a functional relationship
with another c acid sequence. For example, DNA that encodes a presequence or
secretory leader is operably linked to DNA that encodes a polypeptide if it is expressed as a
preprotein that ipates in the secretion of the polypeptide; a promoter or enhancer is
operably linked to a coding sequence if it affects the transcription of the sequence; or a
03_1 ters) 3.NZ 6 04/06/2021
me binding site is operably linked to a coding sequence if it is positioned so as to
facilitate translation. Generally, operably linked means that the DNA sequences being linked
are near each other, and, in the case of a secretory leader, contiguous and in reading phase.
However, enhancers do not have to be contiguous. For example, a nucleic acid sequence that
is operably linked to a second nucleic acid sequence is covalently linked, either directly or
indirectly, to such second sequence, gh any effective three-dimensional association is
acceptable. A single c acid sequence can be operably linked to multiple other
sequences. For example, a single promoter can direct transcription of multiple RNA species.
Linking can be accomplished by ligation at convenient restriction sites. If such sites do not
exist, the synthetic ucleotide adaptors or linkers are used in accordance with
conventional ce.
The terms identical or t identity, in the t of two or more nucleic acids
or polypeptide ces, refer to two or more sequences or subsequences that are the same
or have a specified percentage of amino acid residues or nucleotides that are the same (i.e.,
about 60% identity, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%,
95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and
aligned for m correspondence over a comparison window or designated region) as
measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default
parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI
web site or the like). Such sequences are then said to be substantially identical. This
tion also refers to, or may be applied to, the compliment of a test sequence. The
definition also includes ces that have deletions and/or additions, as well as those that
have tutions. As described below, the preferred algorithms can account for gaps and
the like. Preferably, identity exists over a region that is at least about 25 amino acids or
nucleotides in length, or more preferably over a region that is 50-100 amino acids or
nucleotides in length.
For sequence comparison, lly one sequence acts as a reference sequence, to
which test sequences are compared. When using a sequence comparison algorithm, test and
reference sequences are entered into a computer, subsequence coordinates are designated, if
necessary, and sequence algorithm program parameters are designated. Preferably, default
m parameters can be used, or alternative parameters can be designated. The sequence
comparison algorithm then calculates the percent sequence identities for the test sequences
relative to the reference sequence, based on the program parameters.
17746603_1 (GHMatters) P107943.NZ 7 04/06/2021
A comparison window, as used herein, includes nce to a segment of any one
of the number of contiguous positions selected from the group consisting of from 20 to 600,
usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may
be compared to a reference sequence of the same number of contiguous positions after the
two sequences are optimally aligned. Methods of alignment of sequences for comparison are
well-known in the art. Optimal alignment of sequences for comparison can be conducted,
e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981);
by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970);
by the search for similarity method of Pearson & Lipman, Proc. Nat’l. Acad. Sci. USA
85:2444 (1988); by computerized implementations of these algorithms (GAP, BESTFIT,
FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer
Group, 575 Science Dr., n, WI); or by manual ent and visual inspection (see,
e.g., Current ols in lar Biology (Ausubel et al., eds. 1995 supplement)).
A preferred example of an algorithm that is le for determining t
sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which
are described in Altschul et al., Nuc. Acids Res. 25:3389-3402 (1977), and Altschul et al., J.
Mol. Biol. 215:403-410 (1990), respectively. BLAST and BLAST 2.0 are used, with the
ters described herein, to determine percent sequence identity for nucleic acids or
proteins. Software for performing BLAST analyses is publicly available through the
National Center for Biotechnology Information, as known in the art. This algorithm involves
first identifying high scoring sequence pairs (HSPs) by fying short words of a selected
length (W) in the query sequence, which either match or satisfy some positive-valued
threshold score T when aligned with a word of the same length in a database sequence. T is
referred to as the neighborhood word score threshold (Altschul et al., . These initial
neighborhood word hits act as seeds for initiating searches to find longer HSPs containing
them. The word hits are extended in both directions along each sequence for as far as the
cumulative alignment score can be increased. Cumulative scores are calculated using, for
nucleotide sequences, the parameters M (reward score for a pair of matching es; always
> 0) and N ty score for mismatching residues; always < 0). For amino acid sequences,
a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each
direction are halted when: the cumulative alignment score falls off by the quantity X from its
m achieved value; the cumulative score goes to zero or below, due to the
accumulation of one or more negative-scoring residue ents; or the end of either
sequence is reached. The BLAST algorithm ters W, T, and X determine the
17746603_1 ters) P107943.NZ 8 04/06/2021
sensitivity and speed of the alignment. The Expectation value (E) represents the number of
different alignments with scores equivalent to or better than what is expected to occur in a
database search by chance. The BLASTN program (for tide sequences) uses as
defaults a ngth (W) of 11, an expectation (E) of 10, M=5, N=-4 and a comparison of
both strands. For amino acid ces, the BLASTP program uses as defaults a ngth
of 3, expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff,
Proc. Natl. Acad. Sci. USA 89:10915 (1989)), ents (B) of 50, expectation (E) of 10,
M=5, N=-4, and a comparison of both strands.
The term polypeptide, as used herein, generally has its art-recognized meaning of a
polymer of at least three amino acids and is intended to include peptides and proteins.
r, the term is also used to refer to specific functional classes of polypeptides, such as,
for example, desaturases, elongases, etc. For each such class, the present disclosure provides
several examples of known sequences of such polypeptides. Those of ordinary skill in the art
will appreciate, however, that the term polypeptide is intended to be sufficiently general as to
encompass not only polypeptides having the complete sequence recited herein (or in a
nce or database specifically mentioned herein), but also to ass polypeptides that
represent functional fragments (i.e., fragments retaining at least one activity) of such
complete polypeptides. Moreover, those in the art understand that protein sequences
generally tolerate some substitution without destroying activity. Thus, any polypeptide that
s activity and shares at least about 30-40% overall sequence identity, often greater than
about 50%, 60%, 70%, or 80%, and further usually ing at least one region of much
higher ty, often greater than 90% or even 95%, 96%, 97%, 98%, or 99% in one or more
highly conserved regions, usually encompassing at least 3-4 and often up to 20 or more
amino acids, with another polypeptide of the same class, is encompassed within the relevant
term polypeptide as used herein. Those in the art can determine other regions of similarity
and/or identity by analysis of the sequences of various polypeptides described herein. As is
known by those in the art, a variety of strategies are known, and tools are available, for
performing comparisons of amino acid or nucleotide sequences in order to assess degrees of
identity and/or similarity. These strategies include, for example, manual alignment, computer
assisted ce ent and combinations thereof. A number of algorithms (which are
generally computer implemented) for performing sequence alignment are widely ble, or
can be produced by one of skill in the art. Representative algorithms e, e.g., the local
homology algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2: 482); the homology
alignment algorithm of Needleman and Wunsch (J. Mol. Biol., 1970, 48: 443); the search for
17746603_1 (GHMatters) P107943.NZ 9 04/06/2021
similarity method of Pearson and Lipman (Proc. Natl. Acad. Sci. (USA), 1988, 85: 2444);
and/or by computerized implementations of these algorithms (e.g., GAP, BESTFIT, FASTA,
and TFASTA in the Wisconsin Genetics Software Package e 7.0, Genetics Computer
Group, 575 Science Dr., Madison, Wis.). Readily available computer ms incorporating
such algorithms include, for e, BLASTN, BLASTP, Gapped BLAST, PILEUP,
CLUSTALW, etc. When utilizing BLAST and Gapped BLAST programs, default parameters
of the tive programs may be used. Alternatively, the practitioner may use non-default
ters depending on his or her experimental and/or other requirements (see for example,
the Web site having URL www.ncbi.nlm.nih.gov).
As discussed above, the nucleic acids encoding the xylose transporter, xylulose kinase
and xylose isomerase, can be linked to a er and/or terminator. Examples of ers
and terminators include, but are not limited to, tubulin promoters and terminators. By way of
example, the promoter is a tubulin promoter, e.g., an tubulin promoter. ally, the
promoter is at least 80% identical to SEQ ID NO:25 or SEQ ID NO:26. ally, the
terminator is a tubulin terminator. Optionally, the terminator is at least 80% identical to SEQ
ID NO:27, SEQ ID NO:28, or SEQ ID NO:30.
As used herein, the terms er, promoter t, and regulatory sequence refer
to a polynucleotide that regulates expression of a selected polynucleotide sequence operably
linked to the promoter, and that effects expression of the selected polynucleotide sequence in
cells. The term Thraustochytrium promoter, as used herein, refers to a promoter that
functions in a Thraustochytrium cell. In some embodiments, a promoter element is or
comprises untranslated s (UTR) in a position 5’ of coding sequences. 5’ UTRs form
part of the mRNA transcript and so are an integral part of protein expression in eukaryotic
organisms. Following transcription 5’UTRs can regulate protein expression at both the
transcription and translation levels.
As used herein, the term terminator refers to a polynucleotide that abrogates
expression of, targets for maturation (e.g., adding a polyA tail), or imparts mRNA stability to
a selected polynucleotide sequence operably linked to the terminator in cells. A terminator
sequence may be downstream of a stop codon in a gene. The term Thraustochytrium
terminator, as used herein, refers to a terminator that functions in a Thraustochytrium cell.
Provided herein are also nucleic acid constructs that include c acid sequences encoding
xylose isomerase, xylulose kinase and xylose transporter as well as promoters, terminators,
selectable markers, 2A peptides or any combination f. By way of example, provided is
a first c acid construct including a promoter, a able marker, a nucleic acid
17746603_1 (GHMatters) P107943.NZ 10 04/06/2021
sequence encoding a 2A peptide, a nucleic acid sequence encoding a xylose ase, and a
terminator. Also provided is a second nucleic acid construct including a promoter, selectable
, a nucleic acid ce encoding a 2A peptide, a c acid sequence encoding a
xylulose kinase, and a terminator. Further provided is a third nucleic acid uct including
a promoter, a nucleic acid sequence encoding a xylose transporter, a nucleic acid sequence
encoding a 2A peptide, a able marker, and a ator. These constructs are
ary and the nucleic acid sequences encoding the xylose isomerase, xylulose kinase
and xylose transporter can be included on the same construct under control of the same or
different promoters. Optionally, each of the nucleic acid ces encoding the xylose
isomerase, xylulose kinase and xylose transporter are on the same construct and are separated
by 2A polypeptide sequences, e.g., as shown in SEQ ID NO:6. Thus, by way of example, a
nucleic acid construct can include a tubulin promoter, a nucleic acid sequences encoding a
xylose isomerase, xylulose kinase, and xylose transporter ted by a c acid
sequence encoding SEQ ID NO:6, a tubulin terminator and a selectable marker. Optionally,
the selectable marker is the ble gene. Optionally, the selectable marker comprises SEQ ID
NO:29.
The phrase selectable marker, as used herein, refers either to a nucleotide sequence,
e.g., a gene, that encodes a product (polypeptide) that allows for selection, or to the gene
product (e.g., polypeptide) itself. The term selectable marker is used herein as it is lly
understood in the art and refers to a marker whose presence within a cell or organism confers
a significant growth or survival advantage or antage on the cell or sm under
certain defined culture conditions tive conditions). For example, the conditions may be
the presence or absence of a particular compound or a ular environmental condition
such as increased temperature, increased radiation, presence of a compound that is toxic in
the absence of the marker, etc. The presence or absence of such nd(s) or
environmental condition(s) is referred to as a ive condition or selective conditions. By
growth advantage is meant either enhanced viability (e.g., cells or organisms with the growth
advantage have an increased life span, on average, relative to otherwise identical cells),
increased rate of proliferation (also referred to herein as growth rate) relative to otherwise
identical cells or organisms, or both. In general, a population of cells having a growth
advantage will exhibit fewer dead or nonviable cells and/or a greater rate of cell proliferation
than a population of otherwise identical cells lacking the growth advantage. Although
typically a selectable marker will confer a growth age on a cell, certain selectable
markers confer a growth disadvantage on a cell, e.g., they make the cell more susceptible to
17746603_1 (GHMatters) P107943.NZ 11 04/06/2021
the deleterious effects of certain compounds or environmental conditions than otherwise
cal cells not sing the marker. Antibiotic resistance markers are a non-limiting
example of a class of selectable marker that can be used to select cells that express the
marker. In the ce of an appropriate concentration of antibiotic (selective conditions),
such a marker confers a growth advantage on a cell that expresses the marker. Thus, cells
that express the antibiotic resistance marker are able to survive and/or erate in the
presence of the antibiotic while cells that do not express the antibiotic resistance marker are
not able to survive and/or are unable to proliferate in the presence of the antibiotic.
Examples of able markers include common bacterial antibiotics, such as but not
limited to ampicillin, kanamycin and chloramphenicol, as well as ive compounds
known to function in microalgae; examples include rrnS and AadA (Aminoglycoside 3’-
adenylytranferase), which may be isolated from E. coli plasmid R538-1, conferring resistance
to spectinomycin and streptomycin, respectively in E. coli and some microalgae
(Hollingshead and Vapnek, d 13:17-30, 1985; Meslet-Cladière and Vallon, Eukaryot
Cell. 10(12):1670-8 2011). Another example is the 23S RNA protein, rrnL, which confers
resistance to erythromycin (Newman, Boynton et al., Genetics, 126:875–888 1990; Roffey,
Golbeck et al., Proc. Natl Acad. Sci. USA, 88:9122–9126 1991). Another example is Ble, a
GC rich gene isolated from Streptoalloteichus hindustanus that s resistance to zeocin
(Stevens, Purton et al., Mol. Gen. Genet., 251:23-30 1996). Aph7 is yet another example,
which is a Streptomyces hygroscopicus-derived aminoglycoside phosphotransferase gene that
confers resistance to hygromycin B (Berthold, Schmitt et al., Protist 153(4):401-412 2002).
Additional examples include: AphVIII, a Streptomyces rimosus d lycoside 3′-
otransferase type VIII that confers ance to Paromycin in E. coli and some
microalgae (Sizova, Lapina et al., Gene 181(1-2):13-18 1996; Sizova, Fuhrmann et al., Gene
277(1-2):221-229 2001); Nat & Sat-1, which encode nourseothricin acetyl transferase from
Streptomyces noursei and streptothricin acetyl transferase from E. coli, which confer
ance to nourseothricin (Zaslavskaia, Lippmeier et al., Journal of Phycology 379-
386, 2000); Neo, an aminoglycoside sphotransferase, conferring resistance to the
aminoglycosides; cin, neomycin, and the analog G418 (Hasnain, Manavathu et al.,
Molecular and Cellular Biology 5(12):3647-3650, 1985); and Cry1, a mal protein S14
that confers resistance to emetine (Nelson, Savereide et al., Molecular and Cellular Biology
14(6):4011-4019, 1994).
Other selectable s include nutritional markers, also referred to as auto- or auxotrophic
markers. These include photoautotrophy markers that impose selection based on the
17746603_1 (GHMatters) P107943.NZ 12 04/06/2021
restoration of photosynthetic activity within a photosynthetic organism. Photoautotrophic
markers include, but are not d to, AtpB, TscA, PetB, NifH, psaA and psaB (Boynton,
Gillham et al., Science 240(4858):1534-1538 1988; Goldschmidt-Clermont, Nucleic Acids
Research 19(15):4083-4089, 1991; Kindle, Richards et al., PNAS, 88(5):1721-1725, 1991;
Redding, MacMillan et al., EMBO J 17(1):50-60, 1998; Cheng, Day et al., Biochemical and
Biophysical ch Communications :966-975, 2005). Alternative or additional
nutritional markers include ARG7, which encodes argininosuccinate lyase, a critical step in
arginine biosynthesis hy, Purton et al., EMBO J 8(10):2803-2809, 1989); NIT1, which
encodes a nitrate reductase essential to nitrogen metabolism (Fernández, Schnell et al.,
PNAS, 86(17):6449-6453, 1989); THI10, which is essential to thiamine biosynthesis (Ferris,
Genetics 141(2):543-549, 1995); and NIC1, which catalyzes an essential step in nicotinamide
biosynthesis (Ferris, Genetics 141(2):543-549, 1995). Such markers are generally s
that function in a biosynthetic pathway to produce a compound that is needed for cell growth
or survival. In general, under nonselective conditions, the required nd is present in
the environment or is ed by an alternative pathway in the cell. Under ive
conditions, functioning of the biosynthetic pathway, in which the marker is involved, is
needed to produce the nd.
The phrase selection agent, as used herein refers to an agent that introduces a selective
pressure on a cell or populations of cells either in favor of or against the cell or population of
cells that bear a selectable . For example, , the selection agent is an antibiotic and the
selectable marker is an antibiotic resistance gene. Optionally, zeocin is used as the selection
agent.
Suitable microorganisms that can be transformed with the provided nucleic acids
encoding the genes involved in xylose metabolism and nucleic acid constructs containing the
same include, but are not limited to, algae (e.g., lgae), fungi (including yeast), bacteria,
or protists. Optionally, the microorganism includes Thraustochytrids of the order
Thraustochytriales, more specifically Thraustochytriales of the genus Thraustochytrium.
Optionally, the population of microorganisms includes tochytriales as described in
U.S. Patent Nos. 5,340,594 and 5,340,742, which are incorporated herein by reference in
their ties. The microorganism can be a Thraustochytrium species, such as the
Thraustochytrium s ted as ATCC Accession No. PTA-6245 (i.e., ONC-T18) as
described in U.S. Patent No. 8,163,515, which is incorporated by reference herein in its
entirety. Thus, the microorganism can have an 18s rRNA sequence that is at least 95%, 96%,
17746603_1 (GHMatters) P107943.NZ 13 04/06/2021
97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or
more (e.g., including 100%) cal to SEQ ID NO:1.
Microalgae are acknowledged in the field to represent a diverse group of sms.
For the purpose of this document, the term microalgae will be used to describe unicellular
microorganisms derived from aquatic and/or terrestrial environments (some cyanobacteria are
terrestrial/soil dwelling). Aquatic nments extend from oceanic environments to
freshwater lakes and rivers, and also include brackish nments such as estuaries and
river mouths. Microalgae can be photosynthetic; optionally, microalgae are heterotrophic.
Microalgae can be of eukaryotic nature or of prokaryotic nature. Microalgae can be nonmotile
or motile.
The term thraustochytrid, as used herein, refers to any member of the order
tochytriales, which includes the family Thraustochytriaceae. Strains described as
thraustochytrids include the following organisms: Order: Thraustochytriales; Family:
Thraustochytriaceae; Genera: tochytrium (Species: sp., arudimentale, aureum,
benthicola, globosum, kinnei, motivum, multirudimentale, ermum, proliferum, ,
striatum), Ulkenia (Species: sp., amoeboidea, lensis, minuta, profunda, radiata,
sailens, sarkariana, schizochytrops, visurgensis, yorkensis), Schizochytrium (Species: sp.,
aggregatum, limnaceum, mangrovei, minutum, oruni), chytrium (Species: sp.,
marinum), Aplanochytrium (Species: sp., haliotidis, kerguelensis, profunda, stocchinoϊ),
Althornia (Species: sp., crouchii), or Elina (Species: sp., marisalba, sinorifica). Species
described within Ulkenia will be considered to be members of the genus Thraustochytrium.
Strains described as being within the genus Thrautochytrium may share traits in common
with and also be described as falling within the genus Schizochytrium. For example, in some
taxonomic classifications ONC-T18 may be considered within the genus Thrautochytrium,
while in other classifications it may be bed as within the genus Schizochytrium because
it comprises traits indicative of both genera.
The term transformation, as used herein refers to a s by which an exogenous or
heterologous c acid molecule (e.g., a vector or inant nucleic acid molecule) is
introduced into a recipient cell or microorganism. The exogenous or heterologous nucleic
acid molecule may or may not be integrated into (i.e., covalently linked to) chromosomal
DNA making up the genome of the host cell or microorganism. For example, the exogenous
or heterologous polynucleotide may be maintained on an episomal element, such as a
plasmid. Alternatively or onally, the exogenous or heterologous polynucleotide may
become integrated into a chromosome so that it is inherited by daughter cells through
17746603_1 (GHMatters) P107943.NZ 14 04/06/2021
chromosomal replication. Methods for ormation e, but are not limited to, calcium
ate precipitation; Ca2+ treatment; fusion of recipient cells with bacterial protoplasts
ning the recombinant nucleic acid; treatment of the recipient cells with liposomes
containing the recombinant nucleic acid; DEAE dextran; fusion using polyethylene glycol
(PEG); electroporation; magnetoporation; biolistic delivery; retroviral infection; lipofection;
and micro-injection of DNA directly into cells.
The term transformed, as used in reference to cells, refers to cells that have one
transformation as described herein such that the cells carry ous or heterologous
c material (e.g., a recombinant nucleic acid). The term transformed can also or
alternatively be used to refer to microorganisms, strains of microorganisms, tissues,
organisms, etc. that contain exogenous or heterologous genetic material.
The term introduce, as used herein with reference to uction of a c acid
into a cell or organism, is intended to have its broadest meaning and to encompass
introduction, for example by transformation methods (e.g., calcium-chloride-mediated
transformation, electroporation, particle bombardment), and also introduction by other
methods including transduction, conjugation, and mating. ally, a construct is utilized
to introduce a nucleic acid into a cell or organism.
The microorganisms for use in the methods described herein can produce a variety of
lipid compounds. As used herein, the term lipid includes phospholipids, free fatty acids,
esters of fatty acids, triacylglycerols, sterols and sterol esters, carotenoids, xanthophyls (e.g.,
oxycarotenoids), hydrocarbons, and other lipids known to one of ordinary skill in the art.
Optionally, the lipid compounds include unsaturated lipids. The unsaturated lipids can
include polyunsaturated lipids (i.e., lipids containing at least 2 unsaturated carbon-carbon
bonds, e.g., double bonds) or highly unsaturated lipids (i.e., lipids containing 4 or more
unsaturated carbon-carbon bonds). Examples of unsaturated lipids include omega-3 and/or
omega-6 polyunsaturated fatty acids, such as docosahexaenoic acid (i.e., DHA),
eicosapentaenoic acid (i.e., EPA), and other naturally occurring unsaturated, polyunsaturated
and highly unsaturated nds.
Provided herein are recombinant microorganisms engineered to express
polypeptides for lizing C5 carbon sugars such as xylose. Specifically, provided is a
inant microorganism having one or more copies of a nucleic acid sequence encoding
xylose isomerase, wherein the nucleic acid encoding xylose isomerase is a exogenous c
acid. Optionally, the recombinant microorganism comprises two or more copies of the
nucleic acid sequence encoding xylose isomerase. Optionally, the recombinant
17746603_1 (GHMatters) P107943.NZ 15 04/06/2021
microorganisms also contains one or two copies of an endogenous nucleic acid ce
encoding xylose isomerase. By way of example, the recombinant microorganisms can
contain one or two copies of an endogenous c acid sequence encoding xylose ase
and one copy of an exogenous nucleic acid sequence encoding xylose isomerase. Optionally,
the recombinant rganism includes three copies of a nucleic acid sequence encoding
xylose isomerase, one being exogenously introduced and the other two being nous.
The term recombinant when used with reference to a cell, nucleic acid, polypeptide, vector,
or the like indicates that the cell, nucleic acid, polypeptide, vector or the like has been
modified by or is the result of laboratory methods and is non-naturally occurring. Thus, for
example, recombinant microorganisms include microorganisms produced by or modified by
laboratory methods, e.g., transformation methods for introducing nucleic acids into the
microroganism. Recombinant microorganisms can include nucleic acid sequences not found
within the native (non-recombinant) form of the microroganisms or can include nucleic acid
sequences that have been modified, e.g., linked to a non-native promoter.
As used herein, the term exogenous refers to a substance, such as a nucleic acid (e.g.,
nucleic acids including regulatory sequences and/or genes) or polypeptide, that is cially
uced into a cell or organism and/or does not naturally occur in the cell in which it is
present. In other words, the substance, such as nucleic acid or polypeptide, ates from
outside a cell or organism into which it is introduced. An exogenous c acid can have a
tide ce that is identical to that of a nucleic acid naturally present in the cell. For
example, a Thraustochytrid cell can be engineered to include a nucleic acid having a
Thraustochytrid or tochytrium regulatory sequence. In a particular example, an
endogenous Thraustochytrid or Thraustochytrium regulatory sequence is operably linked to a
gene with which the regulatory sequence is not involved under natural conditions. Although
the tochytrid or Thraustochytrium regulatory sequence may naturally occur in the host
cell, the uced nucleic acid is exogenous according to the present disclosure. An
exogenous nucleic acid can have a nucleotide sequence that is different from that of any
nucleic acid that is naturally present in the cell. For example, the exogenous nucleic acid can
be a heterologous nucleic acid, i.e., a nucleic acid from a different species or organism. Thus,
an exogenous nucleic acid can have a nucleic acid sequence that is identical to that of a
nucleic acid that is naturally found in a source organism but that is different from the cell into
which the exogenous nucleic acid is uced. As used herein, the term endogenous, refers
to a nucleic acid sequence that is native to a cell. As used herein, the term heterologous
refers to a c acid sequence that is not native to a cell, i.e., is from a different organism
17746603_1 (GHMatters) P107943.NZ 16 04/06/2021
than the cell. The terms exogenous and endogenous or logous are not mutually
exclusive. Thus, a nucleic acid sequence can be exogenous and endogenous, meaning the
nucleic acid sequence can be introduced into a cell but have a sequence that is the same as or
similar to the sequence of a nucleic acid naturally present in the cell. Similarly, a nucleic
acid sequence can be exogenous and heterologous meaning the nucleic acid sequence can be
introduced into a cell but have a sequence that is not native to the cell, e.g., a sequence from a
different organism.
As discussed above, the provided recombinant microorganisms n at least two
copies of a nucleic acid sequence encoding a xylose isomerase. The provided
microorganisms optionally also contain at least one c acid sequence encoding a
xylulose kinase. Optionally, the recombinant microorganisms comprise at least one nucleic
acid sequence encoding a xylose orter. The nucleic acid sequences encoding the xylose
isomerase, xylulose , and/or xylose transporter are, optionally, exogenous nucleic acid
sequences. Optionally, the nucleic acid sequence encoding the xylose ase is an
endogenous nucleic acid sequence. Optionally, the nucleic acid sequence encoding the
xylulose kinase and/or xylose transporter is a heterologous nucleic acid. Optionally, the
microorganism contains at least two copies of a nucleic acid sequence encoding a xylose
isomerase, at least two copies of a nucleic acid sequence encoding a xylulose kinase, and at
least one nucleic acid sequence encoding a xylose transporter. Optionally, the heterologous
nucleic acid ce encoding the xylose isomerase is at least 90% identical to SEQ ID
NO:2. Optionally, the heterologous nucleic acid sequence ng the xylulose kinase is at
least 90% identical to SEQ ID NO:5. As noted above, optionally, the nucleic acid encoding
the xylose transporter is a heterologous nucleic acid. ally, the xylose transporter
encoded by the heterologous nucleic acid is GXS1 from Candida intermedia. ally, the
heterologous nucleic acid sequence encoding the xylose transporter is at least 90% identical
to SEQ ID NO:23.
The provided recombinant microorganisms not only contain nucleic acid ces
encoding genes ed in xylose metabolism, they can include multiple copies of such
sequences. Thus, the microorganism ses at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,
39, or 40 copies of the nucleic acid ce encoding xylose isomerase. Optionally, the
microorganism comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 copies of the
nucleic acid sequence encoding the xylulose kinase. Optionally, the microorganism
17746603_1 (GHMatters) 3.NZ 17 04/06/2021
comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,
, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 copies of the c acid
sequence encoding the xylose transporter.
In the provided microorganisms, the nucleic acids, e.g., xylose isomerase, xylulose
kinase or xylose transporter can be operably linked to a promoter and/or terminator.
Optionally, the exogenous nucleic acid sequence encoding the xylose isomerase is operably
linked to a promoter. Optionally, the nucleic acid ce ng the xylulose kinase
and/or the nucleic acid sequence encoding the xylose transporter are also operably linked to a
er. Optionally, the promoter is a tubulin promoter. Optionally, the promoter is at least
80% identical to SEQ ID NO:25 or SEQ ID NO:26. Optionally, the exogenous c acid
sequence encoding the xylose isomerase comprises a terminator. Optionally, the nucleic acid
sequence encoding the xylulose kinase comprises a terminator. Optionally, the nucleic acid
sequence encoding the xylose transporter comprises a terminator. Optionally, the terminator
is a n terminator. Optionally, the terminator is at least 80% identical to SEQ ID NO:27,
SEQ ID NO:28, or SEQ ID NO:30.
The provided microorganisms can include a selectable marker to confirm
transformation of genes of interest. Thus, the microorganism can further include a selectable
marker. Optionally, the selectable marker is an antibiotic resistance gene. Optionally, the
otic is zeocin, ycin B, kanamycin or neomycin. Optionally, the microorganism
is either a Thraustochytrium or a Schizochytrium microorganism. ally, the
microorganism is ONC-T18.
The provided microorganisms have distinguishing features over wild type
microorganisms. For e, the inant microorganisms can have increased xylose
transport activity as compared to a non-recombinant control (or wild type) microorganism,
increased xylose isomerase activity as ed to a non-recombinant control (or wild type)
microorganism, sed xylulose kinase activity as compared to a non-recombinant control
(or wild type) microorganism, or any combination of these activities. Optionally, the
recombinant rganism grows with xylose as the sole carbon source.
Also provided are methods of making the recombinant microorganisms. Thus,
provided is a method of making a recombinant xylose-metabolizing microorganism including
providing one or more c acid constructs comprising a nucleic acid sequence encoding a
xylose ase, a nucleic acid sequence encoding a xylulose kinase and a nucleic acid
sequence encoding a xylose transporter; transforming the microorganism with the one or
more nucleic acid constructs; and isolating microorganisms comprising at least two copies of
17746603_1 ters) P107943.NZ 18 04/06/2021
the nucleic acid sequences encoding the xylose isomerase. Optionally, the methods further
include isolating microorganisms comprising at least two copies of the nucleic acid ce
encoding the xylulose kinase. Optionally, the method es isolating microorganisms
comprising at least one copy of the xylose transporter. Optionally, the one or more nucleic
acid constructs further comprise a selectable marker.
In the provided methods, the nucleic acid sequences encoding the xylose isomerase,
xylulose kinase and xylose transporter can be d on the same or different constructs.
Optionally, the method includes ing a first nucleic acid construct comprising a nucleic
acid sequence encoding a xylose isomerase, a second nucleic acid construct sing a
nucleic acid sequence encoding a xylulose kinase and a third nucleic acid construct
comprising a nucleic acid sequence encoding a xylose transporter. Optionally, the first,
second and third nucleic acid constructs comprise the same selectable marker. Optionally,
the first nucleic acid construct comprises a er, a selectable marker, a nucleic acid
sequence encoding a 2A peptide, the nucleic acid ce ng the xylose isomerase,
and a terminator. Optionally, the second nucleic acid construct comprises a promoter,
selectable marker, a nucleic acid sequence encoding a 2A peptide, the nucleic acid sequence
encoding the xylulose kinase, and a terminator. Optionally, the third nucleic acid construct
comprises a promoter, the nucleic acid sequence encoding the xylose transporter, a nucleic
acid sequence encoding a 2A peptide, a selectable marker, and a terminator. As noted above,
selectable markers include, but are not limited to, antibiotic resistance genes. Optionally, the
antibiotic is zeocin, hygromycin B, kanamycin or neomycin. Promoters used for the
constructs include, but are not limited to, a tubulin promoter. Optionally, the er is at
least 80% identical to SEQ ID NO:25 or SEQ ID NO:26. Terminators used for the constructs
e, but are not limited to, a tubulin terminator. Optionally, the terminator is at least 80%
identical to SEQ ID NO:27, SEQ ID NO:28, or SEQ ID NO:30.
In the provided methods, the isolated recombinant microorganisms can include one or
more copies of the xylose isomerase, xylulose kinase and xylose transporter. Optionally, the
isolated recombinant microorganism comprise at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39,
or 40 copies of the c acid sequence encoding xylose ase. Optionally, the xylose
isomerase is an endogenous xylose isomerase or a heterologous xylose isomerase.
Optionally, the c acid sequence encoding the xylose isomerase is at least 90% identical
to SEQ ID NO:2. Optionally, the isolated recombinant microorganism ses at least 2,
3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29,
17746603_1 ters) P107943.NZ 19 04/06/2021
, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 copies of the nucleic acid sequence encoding the
xylulose kinase. Optionally, the se kinase is a heterologous xylulose kinase.
Optionally, the c acid sequence encoding the xylulose kinase is at least 90% identical to
SEQ ID NO:5. Optionally, the isolated recombinant microorganism comprises at least 2, 3,
4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,
31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 copies of the nucleic acid sequence encoding the
xylose transporter. Optionally, the xylose transporter is a logous xylose transporter.
ally, the xylose transporter is GXS1 from a intermedia. Optionally, the nucleic
acid sequence encoding the xylose transporter is at least 90% identical to SEQ ID NO:23.
Optionally, the microorganism is either a Thraustochytrium or a Schizochytrium
microorganism. Optionally, the rganism is ONC-T18.
As noted above, the isolated recombinant microorgansims can have increased xylose
transport activity as compared to a control non-recombinant microorganism, increased xylose
isomerase activity as ed to a control combinant microorganism, increased
xylulose kinase activity as compared to a control non-recombinant microorganism, or a
combination thereof. Optionally, the isolated recombinant microorganism grows with xylose
as the sole carbon .
As described herein, a control or standard control refers to a sample, measurement,
or value that serves as a reference, usually a known reference, for comparison to a test
sample, measurement, or value. For example, a test rganism, e.g., a microorganism
transformed with c acid sequences encoding genes for metabolizing xylose can be
compared to a known normal (wild-type) microorganism (e.g., a standard control
rganism). A standard control can also represent an average measurement or value
gathered from a population of microorganisms (e.g., standard control microorganisms) that
do not grow or grow poorly on xylose as the sole carbon source or that do not have or have
minimal levels of xylose isomerase activity, xylulose kinase activity and/or xylose transport
activity. One of skill will recognize that standard controls can be designed for assessment of
any number of parameters (e.g., RNA levels, polypeptide levels, specific cell types, and the
like).
ed herein are also s of producing oil using the recombinant
microorganisms. The method includes providing the recombinant microorganism, wherein
the microorganism grows on xylose as the sole carbon source, and culturing the
microorganism in a culture medium under suitable conditions to produce the oil. Optionally,
the oil comprises triglycerides. ally, the oil comprises alpha linolenic acid,
17746603_1 (GHMatters) P107943.NZ 20 04/06/2021
arachidonic acid, docosahexanenoic acid, docosapentaenoic acid, eicosapentaenoic acid,
gamma-linolenic acid, linoleic acid, nic acid, or a ation thereof. ally, the
method further includes isolating the oil.
The provided s include or can be used in conjunction with additional steps
for culturing microorganisms according to methods known in the art. For example, a
Thraustochytrid, e.g., a Thraustochytrium sp., can be cultivated ing to methods
described in U.S. Patent Publications 2009/0117194 or 2012/0244584, which are herein
incorporated by reference in their entireties for each step of the methods or composition used
therein.
Microorganisms are grown in a growth medium (also known as culture medium).
Any of a variety of medium can be suitable for use in culturing the microorganisms described
herein. Optionally, the medium supplies s nutritional components, including a carbon
source and a nitrogen source, for the microorganism. Medium for Thraustochytrid culture
can include any of a variety of carbon s. Examples of carbon sources include fatty
acids, lipids, glycerols, triglycerols, carbohydrates, polyols, amino , and any kind of
biomass or waste stream. Fatty acids include, for example, oleic acid. Carbohydrates
include, but are not limited to, glucose, cellulose, hemicellulose, fructose, dextrose, xylose,
lactulose, galactose, maltotriose, maltose, lactose, glycogen, n, starch (corn or wheat),
acetate, m-inositol (e.g., derived from corn steep liquor), galacturonic acid (e.g., derived from
pectin), L-fucose (e.g., derived from galactose), biose, glucosamine, alpha-D-glucose-
1-phosphate (e.g., derived from glucose), cellobiose, n, cyclodextrin (e.g.,
derived from starch), and e (e.g., from molasses). Polyols include, but are not d
to, maltitol, erythritol, and adonitol. Amino sugars include, but are not limited to, N-acetyl-
D-galactosamine, N-acetyl-D-glucosamine, and N-acetyl-beta-D-mannosamine.
Optionally, the microorganisms provided herein are cultivated under conditions that
increase biomass and/or production of a compound of interest (e.g., oil or total fatty acid
(TFA) content). Thraustochytrids, for example, are typically cultured in saline medium.
ally, Thraustochytrids can be cultured in medium having a salt tration from
about 0.5 g/L to about 50.0 g/L. Optionally, Thraustochytrids are cultured in medium having
a salt concentration from about 0.5 g/L to about 35 g/L (e.g., from about 18 g/L to about 35
g/L). Optionally, the Thraustochytrids described herein can be grown in low salt conditions.
For example, the Thraustochytrids can be cultured in a medium having a salt concentration
from about 0.5 g/L to about 20 g/L (e.g., from about 0.5 g/L to about 15 g/L). The culture
17746603_1 (GHMatters) P107943.NZ 21 04/06/2021
medium optionally includes NaCl. Optionally, the medium includes natural or artificial sea
salt and/or cial seawater.
The culture medium can include non-chloride-containing sodium salts as a source of
sodium. Examples of non-chloride sodium salts suitable for use in accordance with the
present methods include, but are not limited to, soda ash (a mixture of sodium carbonate and
sodium oxide), sodium ate, sodium bicarbonate, sodium sulfate, and mixtures thereof.
See, e.g., U.S. Pat. Nos. 5,340,742 and 6,607,900, the entire contents of each of which are
incorporated by reference herein. A significant portion of the total sodium, for example, can
be supplied by loride salts such that less than about 100%, 75%, 50%, or 25% of the
total sodium in culture medium is supplied by sodium chloride.
Medium for Thraustochytrids culture can include any of a variety of nitrogen sources.
Exemplary en sources include ammonium solutions (e.g., NH4 in H2O), um or
amine salts (e.g., (NH4)2SO4, (NH4)3PO4, NH4NO3, H2CH3 (NH4Ac)), peptone,
tryptone, yeast extract, malt extract, fish meal, sodium glutamate, soy extract, casamino acids
and distiller grains. Concentrations of nitrogen sources in suitable medium typically range
between and including about 1 g/L and about 25 g/L.
The medium optionally includes a phosphate, such as potassium phosphate or sodiumphosphate.
Inorganic salts and trace nutrients in medium can include ammonium e,
sodium bicarbonate, sodium orthovanadate, potassium chromate, sodium molybdate, selenous
acid, nickel sulfate, copper sulfate, zinc sulfate, cobalt chloride, iron chloride, manganese
chloride calcium chloride, and EDTA. Vitamins such as pyridoxine hydrochloride, ne
hydrochloride, calcium pantothenate, p-aminobenzoic acid, riboflavin, nic acid, biotin,
folic acid and vitamin B12 can be included.
The pH of the medium can be adjusted to between and including 3.0 and 10.0 using
acid or base, where appropriate, and/or using the nitrogen source. Optionally, the medium
can be ized.
Generally a medium used for culture of a microorganism is a liquid medium.
However, the medium used for culture of a microorganism can be a solid medium. In
addition to carbon and nitrogen sources as discussed herein, a solid medium can contain one
or more components (e.g., agar or agarose) that provide structural support and/or allow the
medium to be in solid form.
Optionally, the resulting biomass is rized to inactivate undesirable substances
present in the biomass. For example, the biomass can be pasteurized to inactivate compound
degrading substances. The biomass can be t in the tation medium or isolated
17746603_1 (GHMatters) P107943.NZ 22 04/06/2021
from the fermentation medium for the pasteurization step. The pasteurization step can be
performed by heating the biomass and/or fermentation medium to an elevated ature.
For example, the biomass and/or fermentation medium can be heated to a temperature from
about 50°C to about 95°C (e.g., from about 55°C to about 90°C or from about 65°C to about
80°C). Optionally, the s and/or fermentation medium can be heated from about 30
minutes to about 120 minutes (e.g., from about 45 minutes to about 90 minutes, or from about
55 minutes to about 75 minutes). The pasteurization can be performed using a suitable
heating means, such as, for e, by direct steam injection.
Optionally, no pasteurization step is performed. Stated differently, the method taught
herein optionally lacks a pasteurization step.
Optionally, the biomass can be harvested according to a variety of methods, including
those currently known to one skilled in the art. For example, the biomass can be collected
from the fermentation medium using, for example, centrifugation (e.g., with a solid-ejecting
centrifuge) or filtration (e.g., cross-flow filtration). Optionally, the harvesting step es
use of a precipitation agent for the accelerated collection of cellular biomass (e.g., sodium
phosphate or calcium chloride).
Optionally, the biomass is washed with water. Optionally, the biomass can be
concentrated up to about 20% solids. For example, the biomass can be concentrated to about
% to about 20% solids, from about 7.5% to about 15% solids, or from about solids to about
% solids, or any percentage within the recited ranges. Optionally, the biomass can be
concentrated to about 20% solids or less, about 19% solids or less, about 18% solids or less,
about 17% solids or less, about 16% solids or less, about 15% solids or less, about 14% solids
or less, about 13% solids or less, about 12% solids or less, about 11% solids or less, about
% solids or less, about 9% solids or less, about 8% solids or less, about 7% solids or less,
about 6% solids or less, about 5% solids or less, about 4% solids or less, about 3% solids or
less, about 2% solids or less, or about 1% solids or less.
The provided methods, optionally, include isolating the polyunsaturated fatty acids
from the s or microorganisms. Isolation of the saturated fatty acids can be
performed using one or more of a variety of methods, ing those currently known to one
of skill in the art. For example, methods of isolating polyunsaturated fatty acids are
bed in U.S. Patent No. 8,163,515, which is incorporated by reference herein in its
entirety. Optionally, the medium is not sterilized prior to isolation of the polyunsaturated
fatty acids. ally, sterilization comprises an increase in temperature. Optionally, the
saturated fatty acids produced by the microorganisms and isolated from the provided
17746603_1 ters) P107943.NZ 23 04/06/2021
methods are medium chain fatty acids. ally, the one or more saturated fatty
acids are selected from the group consisting of alpha linolenic acid, arachidonic acid,
docosahexanenoic acid, docosapentaenoic acid, eicosapentaenoic acid, gamma-linolenic acid,
linoleic acid, linolenic acid, and combinations thereof.
Oil including polyunsaturated fatty acids (PUFAs) and other lipids produced
according to the method described herein can be utilized in any of a variety of applications
exploiting their biological, nutritional, or al properties. Thus, the provided methods
optionally include isolating oil from the harvested portion of the threshold volume.
Optionally, the oil is used to e fuel, e.g., biofuel. Optionally, the oil can be used in
pharmaceuticals, food supplements, animal feed additives, cosmetics, and the like. Lipids
ed according to the methods described herein can also be used as intermediates in the
production of other compounds.
By way of e, the oil produced by the microorganisms cultured using the
provided methods can comprise fatty acids. Optionally, the fatty acids are selected from the
group ting of alpha nic acid, arachidonic acid, docosahexaenoic acid,
docosapentaenoic acid, eicosapentaenoic acid, gamma-linolenic acid, linoleic acid, linolenic
acid, and ations thereof. Optionally, the oil comprises triglycerides. Optionally, the
oil comprises fatty acids selected from the group consisting of palmitic acid (C16:0), myristic
acid (C14:0), palmitoleic acid (C16:1(n-7)), cis-vaccenic acid (C18:1(n-7)),
docosapentaenoic acid (C22:5(n-6)), docosahexaenoic acid (C22:6(n-3)), and combinations
Optionally, the lipids produced according to the methods described herein can be
incorporated into a final product (e.g., a food or feed supplement, an infant formula, a
pharmaceutical, a fuel, etc.). Suitable food or feed supplements into which the lipids can be
incorporated include beverages such as milk, water, sports drinks, energy drinks, teas, and
juices; confections such as candies, jellies, and biscuits; fat-containing foods and beverages
such as dairy products; processed food products such as soft rice (or porridge); infant
formulae; ast cereals; or the like. Optionally, one or more ed lipids can be
incorporated into a dietary supplement, such as, for example, a vitamin or multivitamin.
Optionally, a lipid produced according to the method described herein can be included in a
dietary supplement and optionally can be directly incorporated into a component of food or
feed (e.g., a food supplement).
Examples of feedstuffs into which lipids produced by the methods described herein
can be incorporated include pet foods such as cat foods; dog foods; feeds for aquarium fish,
17746603_1 ters) 3.NZ 24 04/06/2021
cultured fish or crustaceans, etc.; feed for aised animals (including livestock and fish or
crustaceans raised in aquaculture). Food or feed material into which the lipids produced
according to the methods described herein can be incorporated is ably ble to the
organism which is the intended recipient. This food or feed al can have any physical
properties currently known for a food material (e.g., solid, liquid, soft).
Optionally, one or more of the produced compounds (e.g., PUFAs) can be
incorporated into a nutraceutical or pharmaceutical product. Examples of such a
euticals or pharmaceuticals e various types of tablets, capsules, drinkable agents,
etc. Optionally, the nutraceutical or pharmaceutical is suitable for topical application.
Dosage forms can include, for example, capsules, oils, granula, a subtilae, pulveres,
tabellae, pilulae, trochisci, or the like.
The oil or lipids produced according to the s described herein can be
incorporated into products as described herein in combination with any of a variety of other
agents. For instance, such compounds can be combined with one or more binders or fillers,
chelating agents, pigments, salts, surfactants, moisturizers, viscosity modifiers, thickeners,
emollients, fragrances, preservatives, etc., or any combination thereof.
Disclosed are materials, compositions, and components that can be used for, can be
used in conjunction with, can be used in preparation for, or are products of the disclosed
methods and compositions. These and other als are disclosed herein, and it is
understood that when combinations, s, interactions, groups, etc. of these als are
disclosed that while specific reference of each various individual and collective combinations
and permutations of these compounds may not be explicitly disclosed, each is specifically
contemplated and described herein. For example, if a method is disclosed and discussed and
a number of cations that can be made to a number of molecules including the method
are discussed, each and every combination and ation of the method, and the
modifications that are possible are specifically contemplated unless specifically indicated to
the contrary. se, any subset or combination of these is also specifically contemplated
and disclosed. This concept applies to all aspects of this sure including, but not limited
to, steps in methods using the disclosed compositions. Thus, if there are a variety of
additional steps that can be performed, it is understood that each of these additional steps can
be performed with any specific method steps or combination of method steps of the sed
methods, and that each such combination or subset of combinations is specifically
contemplated and should be ered disclosed.
17746603_1 (GHMatters) P107943.NZ 25 04/06/2021
Publications cited herein and the material for which they are cited are hereby
specifically incorporated by reference in their entireties.
The es below are intended to further illustrate certain aspects of the s
and compositions described herein, and are not intended to limit the scope of the claims.
Example 1. C5 Carbon Metabolism by Recombinant tochytrids
In nature, two xylose metabolism pathways exist, the xylose reductase/xylitol
dehydrogenase pathway and the xylose isomerase/xylulose kinase pathway (Figure 1). ONCT18
encodes genes from both pathways, and, as described above, the xylose reductase/xylitol
dehydrogenase y is dominant, as evidenced by a up of xylitol when grown in a
xylose medium. Since the isomerase/kinase y does not depend on redox co-factors,
over-expression of ONC-T18’s isomerase gene removes tor dependence in the
conversion of xylose to xylulose. As shown herein in Figures 2 and 3, transcriptomic studies
with ONC-T18 showed that its xylose isomerase and putative xylulose kinase genes were
mostly expressed during glucose starvation; whereas, the putatively identified genes encoding
for the xylose reductase and xylitol dehydrogenase were constitutively expressed.
T18 isomerase was purified by metal-affinity chromatography following gging
and over-expression in yeast INVSc1. As a positive control, his-tagged XylA from E. coli
strain W3110 was over-expressed and purified from E. coli strain BL21(DE3)plysS. The
protein concentration of purified proteins was determined by a standard Bradford assay. The
impact of temperature on the activity of T18 isomerase and E. coli isomerase was determined
using 5 µg of protein and 0.75 g/L of either xylose or xylulose in 5mM MgATP, 50mM
Hepes (pH 7.4), 10 mM MgCl2. ons were incubated overnight at 10 °C, 25 °C, 30 °C,
37 °C, 50 °C, 60 °C, and 80 °C. Reactions were stopped by heat vation at 95 ˚C for 5
mins. Reactions were analyzed by HPLC and the concentration of the sugars present was
determined from the area under the peak relative to a rd curve. T18 isomerase had
higher activity on both xylose and xylulose at temperatures at and above 37 °C (Figure 20A).
This is in contrast to E. coli ase, which had higher activity at temperatures between 25
°C and 30°C (Figure 20B).
Dose-dependency was determined by incubating increasing protein concentrations
of the isomerase with 0.75 g/L xylose or xylulose in 5mM MgATP, 50mM Hepes (pH 7.4),
mM MgCl2. Reactions were incubated overnight at 30˚C (E. coli) or 50˚C (T18) then
stopped by heat inactivation at 95 ˚C for 5 mins. Reactions were analyzed by HPLC and the
concentration of the sugars present was ined from the area under the peak relative to a
17746603_1 (GHMatters) P107943.NZ 26 04/06/2021
standard curve. Observed was a dose ency of T18 isomerase on both xylose and
se (Figures 21A and 21B).
This example describes the use of a Thraustochytrium ONC-T18-derived 8
) alpha-tubulin promoter to express endogenous and/or heterologous xylose metabolism
transgenes in Thraustochytrid species, including ONC-T18. However, as discussed
throughout, other regulatory elements can be used. Figures 4 and 5 show constructs of the
plasmids containing the xylose isomerase and xylulose kinase genes, respectively. As
described herein, the xylose metabolism transgenes were present in multiple (≥8) copies
within the genome of the host. In the case of 8, the modified organisms
demonstrated an sed metabolism of xylose compared to wild-type (WT) cells. For
example, a strain ed to express an endogenous xylose isomerase gene (SEQ ID NO:2)
(strain s #16) and a strain ed to express an endogenous xylose isomerase gene
(SEQ ID NO:2) and a se kinase gene (SEQ ID NO:5) (Iso-His+xylB, strain 7-7) both
used 40% more xylose than the WT strain. Both Iso-His #16 and 7-7 converted less xylose to
xylitol than the WT strain, 40% less and 420% less, respectively. The constructs used for
transformation of ONC-T18 are shown in Figures 4 and 5. ONC-T18 tranformants were
d using standard biolistics protocols as described by BioRad’s Biolistic PDS-1000/He
Particle Delivery System (Hercules, CA). Briefly, 0.6 µm gold particles were coated with 2.5
µg of linerized plasmid DNA , 37˚C, overnight). The coated gold particles were used
to bombard plates previously spread with 1 ml of ONC-T18 cells at an OD600 of 1.0. The
bombardment parameters included using a helium pressure of 1350 or 1100 psi with a target
distance of 3 or 6 cm. After an overnight recovery, the cells were washed off the plate and
plated on media containing selection antibiotics (Zeo 250 µg/mL and hygro 400 µg/mL).
Plates were incubated for 1 week at 25˚C to identify resistant colonies. The resulting
transformants were screened by PCR and Southern blot.
rn blots were performed using standard protocols. Briefly, approximately 20
µg of genomic DNA were digested with 40 units of BamHI restriction enzyme in a total
volume of 50 µL overnight at 37˚C. 7.2 µg of each digested sample was run on a 1.0%
agarose gel at 50V for approximately 1.5. hours, with a digoxigenin (DIG) DNA molecularweight
marker II (Roche, Basel, Switzerland). DNA was depurinated in the gel by
submerging the gel in 250 mM HCl for 15 minutes. The gel was further denatured by
incubation in a solution containing 0.5 M NaOH and 1.5 M NaCL (pH 7.5) for two 15 minute
washes. The on was then neutralized by incubation in 0.5 M Cl (pH 7.5) for two
minute washes. y, the gel was equilibrated in 20X saline-sodium citrate (SSC) buffer
17746603_1 (GHMatters) P107943.NZ 27 04/06/2021
for 15 minutes. DNA was transferred to a positively charged nylon membrane using a
standard transfer apparatus. DNA was fixed to the membrane using a UV Stratalinker at an
exposure of 120,000 µJ. Southern blot probe was generated using a PCR DIG Probe
Synthesis Kit (Roche, Basel, Switzerland) to generate a DIG-labelled probe according to the
manufacturer’s instructions. The DNA affixed to the nylon ne was prehybridized
with 20 mL of DIG EasyHyb solution (DIG EasyHyb Granules, Roche, Basel, Switzerland).
The belled probe was red by adding 40 µL of the ble-probe reaction mixture to
300 µL of ddH2O and incubated at 99˚C for 5 minutes. This solution was then added to 20
mL of DIG hybridization solution to create the probe solution. The probe solution was then
added to the DNA-affixed nylon membrane and incubated at 53 ˚C overnight. The following
day, the membrane was washed twice in 2X SSC, 0.1% SDS at room ature. The
membrane was further washed twice in 0.1X SSC, 0.1% SDS at 68˚C for 15 minutes. For
ion, the membrane was washed and blocked using DIG Wash and Block Buffer set
(Roche, Basel, Switzerland) according to the manufacturer’s instructions. An anti-DIG-AP
conjugated dy from a DIG Nucleic Acid Detection Kit (Roche, Basel, rland) was
used for detection. 2 µL of the antibody solution was added to 20mL detection solution and
incubated with the membrane at room temperature for 30 minutes. The blot was then
immersed in a washing buffer provided with the kit. CDP-Star (Roche, Basel, Switzerland)
was used for visualization. 10 µL of the CDP-star on was incubated on the membrane in
1 mL of detection solution, which was covered in a layer of ‘sheet-protector’ plastic to hold
the on to the membrane. Signal was ately detected using a oc imaging
system (BioRad Laboratories, Hercules, CA).
The codon optimized ble gene was cloned under the control of T18B α-tubulin
promoter and terminator elements (Figure 6). The isomerase gene was cloned from T18B in
such a way as to add a six-histidine tag on the N-terminus of the expressed protein (Iso-His).
Xylose isomerase tic activity was confirmed by over-expression and purification of
the histidine-tagged protein in yeast. The isomerase gene (along with the introduced six-
histidine tag) was cloned under the control of the α-tubulin promoter and terminators by
g the gene downstream of the ble gene and a 2A sequence (Figure 4 and Figure 6).
Biolistic transformation of T18B with this plasmid (pALPHTB-B2G-hisIso) resulted in
Zeocin (zeo) resistant transformants. Many transformant strains were obtained from this
procedure. Two of these strains are shown as example #6 containing one copy of the
transgene and e #16 containing eight copies of the transgene (Figure 7).
17746603_1 (GHMatters) P107943.NZ 28 04/06/2021
The insertion of the Iso-His transgene within the T18B genome was confirmed by
PCR and Southern blot analysis (Figure 7). atively, these data showed the presence of a
single copy of the transgene in strain #6 and multiple, concatameric, ene copies, at a
single site, in strain #16. The precise number of Iso-His transgene insertions was determined
by qPCR on c DNA (Figure 8). These data showed the presence of one copy of the
transgene in strain #6 and eight copies of the transgene in strain #16 (Figure 8). To test
whether an increase in copy number correlated with an increase in sion level, mRNA
was isolated from WT, Iso-His #6 and Iso-His #16 T18B cells and qRT-PCR was performed.
Figure 11 shows significantly sed expression of the Iso-His transcript in strain #16
cells, ning eight copies of the transgene, compared to strain #6, containing a single
copy of the transgene. No s transcript is detectable in WT cells (Figure 11). To assess
whether increased mRNA expression correlated with increased isomerase enzymatic activity,
cell extracts were harvested from WT, Iso-His #6 and s #16 cells. ed isomerase
enzyme activity is observed in strain #16 cells compared with strain #6 and WT cells (Figure
12). Finally, the ability of strain #16 to metabolize xylose was examined in xylose depletion
assays (Figure 14) and compared with WT cells. These flask fermentations demonstrated the
ability to metabolise xylose and quantify the amount of xylose converted to xylitol. Thus,
Figure 14 shows an increase in xylose metabolism in s strain #16 compared with WT
cells and significantly less production of xylitol.
For flasks assays, cells were grown in media for 2 to 3 days. s were washed
twice in Media 2 (9 g/L NaCl, 4 g/L MgSO4, 100 mg/L CaCl2, 5 mg/L FeCl3, 20 g/L
(NH4)2SO4, 0.86 g/L KH2PO4, 150 µg/L vitamin B12, 30 µg/L biotin, 6 mg/L thiamine
hydrochloride, 1.5 mg/L cobalt (II) chloride, 3 mg/L manganese chloride) containing no
sugar. Then, minimal media containing 20 g/L glucose & 50 g/L xylose was ated to an
OD600 of 0.05 with the washed cells. s were taken at various time points and the
amount of sugar remaining in the supernatant was analyzed by HPLC. As shown in Figures
22A, 22B, 22C and 22D, with increased xylose isomerase gene copy number, up to 40%
more xylose usage and 20% decrease in xylitol production when compared to WT.
Iso-His strain #16 was then used as the parent strain for a second round of
transformation to introduce the E. coli xylB gene. This gene was introduced under
hygromycin (hygro) selection. The hygro gene from pChlamy_3, the 2A sequence, and the
T18B codon optimized W3110 E. coli xylB gene were cloned under the control of the T18B
α-tubulin promoter and terminator elements for expression in T18B iso-his #16 (Figure 5).
The in vitro ability of the E. coli xylulose kinase to work in concert with the T18B isomerase
17746603_1 (GHMatters) P107943.NZ 29 04/06/2021
was confirmed by over-expression and purification of the histidine-tagged proteins in yeast
followed by enzymatic reactions with xylose and xylulose. Biolistic ormation of T18B
iso-his strain #16 with the xylB plasmid (pJB47) resulted in hygro and zeo resistant
transformants. The insertion of the hygro-2A-xylB genes within the T18B genome was
confirmed by PCR and Southern blot analysis (Figure 9). Qualitatively, these data show the
ce of a single copy of the transgene in strain #7-3 and multiple, concatameric,
transgene copies, at a single site, in strain #7-7. The number of xylB gene insertions was
determined by qPCR on genomic DNA isolations (Figure 10). Figure 10 shows sixteen
ions of the transgene in strain 7-7 and one copy in strain 7-3. To determine whether
le copies of the transgene confer enhanced xylose metabolism in vitro, cell extract
assays were performed and the ability of the cells extracts to metabolise xylose was analysed
e 13). The ability of the ormant cells to metabolize xylose was examined through
flask-based xylose depletion assays (Figure 15). In this ment, WT cells consumed the
least amount of xylose and made the most xylitol. Strain Iso-His #16, 7-3 and 7-7 all
consumed similar amounts of xylose; however, only 7-7, containing multiple copies of the
xylB transgene, did not make significant amounts of xylitol. Finally, strains Iso-His #16 and
7-7 were tested at in 5L fermentation vessels in media containing glucose and . During
a seventy-seven (77) hour fermentation, strain Iso-His #16 ted approximately 8% of
xylose to xylitol, whereas strain 7-7 converted approximately 2% of xylose to xylitol. Xylitol
accumulation in this fermentation is shown in Figure 16.
For flasks assays, cells were grown in media for 2 to 3 days. Pellets were washed
twice in media containing no sugar. Media containing 20 g/L: 50 g/L glucose: xylose was
inoculated to an OD600 of 0.05 with the washed cells. s were taken at various time
points and the amount of sugar ing in the supernatant was analyzed by HPLC. As
shown in Figures 23A, 23B, 23C and 23D, up to 50% more xylose was used and an 80%
reduction in xylitol was ed in strains over-expressing both a xylose isomerase and a
xylulose kinase when compared to WT.
To further analyze these strains, the strains were grown in el 5L Sartorius
fermenters. Initial media contained 20g/L Glucose and 50g/L xylose along with other basal
media ents. Both cultures were maintained at 28°C and 5.5 pH, with constant mixing
at 720 RPM and constant aeration at 1 Lpm of environmental air. The cultures were fed
glucose for 16 hrs followed by 8hr starvation period. This cycle was completed 3 times.
During starvation periods, 10mL s were taken every 0.5 hr. Glucose, xylose and
xylitol concentrations were quantified in these samples by HPLC. Larger 50mL samples were
17746603_1 (GHMatters) P107943.NZ 30 04/06/2021
taken ically for r biomass and oil content quantification. e feed rates
d glucose ption rates, which was quantified by CO2 detected in the culture
exhaust gas. As shown in Figure 24, the 7-7 strain used up to 52% more xylose than WT
under these conditions.
By Southern blot analysis, it was observed that strain Iso-His #16 contains eight (8)
insertions of the isomerase transgene (Figure 8). This unexpected multiple insertion resulted
in an increase in isomerase gene expression relative to strains harbouring a single copy
(Figure 11) as well as increased isomerase in vitro activity (Figure 12). Strain s #16
demonstrated increased xylose productivity than strains harbouring a single copy of the
isomerase transgene (Figure 14).
Similarly, within the Iso-His + xylB transformants, one of the clones (Iso-His + xylB
7-7) also had multiple insertions of the xylB gene (Figure 10), which resulted in increased in
vivo activity of both the xylose isomerase and xylulose kinase within the cell (Figure 13).
This clone was capable of using either as much or more xylose than the parental strain, Iso-
His #16, while producing significantly less xylitol (Figure 15). rmore the Iso-His +
xylB 7-7 produced more biomass than WT in the presence of xylose. These two strains
showed that, not only is the presence of both the isomerase and the kinase genes important,
but the number of insertions is as well.
To further optimize the iso-his & xylB containing “7-7” strain, this strain was
transformed with a xylose transporter. Figure 17 shows exemplary constructs for
transformation. Examples of xylose transporters to be used e, but are not limited to,
At5g17010 and At5g59250 dopsis na), Gfx1 and GXS1 (Candida), AspTx
(Aspergillus), and Sut1 (Pichia). Gxs1 (SEQ ID NO:23) was selected for transformation.
The results are shown in Figures 19A, 19B, and 19C. The transformants 36-2, 36-9, and 36-
16, containing GXS1 use more xylose than 7-7 and WT strains. They also use glucose slower
than WT and 7-7 strains. The data demonstrate both xylose and glucose being used in the
earlier stages by the GXS1 containing strains. Further, the percent of xylitol made by the
GXS1 containing strains is lower than both WT and 7-7 strains.
To further analyze the effect of sugar transporters on the metabolism of xylose,
codon optimized xylose transporters AspTX from Aspergillus (An11g01100) and Gxs1 from
a were introduced in the 7-7 strain (isohis + xylB). Figure 25 shows the alpha-tubulin
aspTx-neo and alpha-tubulin gxs1-neo constructs. T18 transformants were created using
standard biolistics protocols as described by BioRad’s tic PDS-1000/He le
Delivery System. Briefly, 0.6 µm gold particles were coated with 2.5 µg of linearized
17746603_1 (GHMatters) 3.NZ 31 04/06/2021
d DNA (EcoRI, 37˚C, o/n), The coated gold particles were used to bombard WD plates
previously spread with 1 ml of T18 cells at an OD600 of 1.0. The bombardment parameters
included using a Helium pressure of 1350 or 1100 psi with a target distance of 3 or 6 cm.
After an overnight ry, the cells were washed off the plate and plated on media
containing selection antibiotics (G418 at 2 mg/mL). Plates were incubated for 1 week at 25˚C
to identify ant colonies. The resulting transformants were screened by PCR and
Southern blot (Figure 26).
Southern blots were med using standard protocols. Briefly, approximately 20
µg of genomic DNA were digested with 40 units of BamHI restriction enzyme in a total
volume of 50 µL o/n/ at 37˚C. 7.2 µg of each digested sample was run on a 1.0% agarose gel
at 50V for approximately 1.5. hours, with a digoxigenin (DIG) DNA molecular-weight
marker II (Roche). DNA was depurinated in the gel by submerging the gel in 250 mM HCl
for 15 minutes. The gel was r denatured by incubation in a solution containing 0.5 M
NaOH and 1.5 M NaCL (pH 7.5) for two 15 minute washes. The on was then
neutralized by incubation in 0.5 M Tris-HCl (pH 7.5) for two 15 minute washes. Finally, the
gel was equilibrated in 20X saline-sodium citrate (SSC) buffer for 15 minutes. DNA was
transferred to a positively charged nylon membrane (Roche) using a standard er
apparatus. DNA was fixed to the membrane using a UV Stratalinker at an exposure of
120,000 µJ. Southern blot probe was generated using a PCR DIG Probe Synthesis Kit
(Roche) to generate a DIG-labelled probe ing to the manufacturer’s ctions. The
DNA affixed to the nylon membrane was prehybridised with 20 mL of DIG EasyHyb
solution (DIG EasyHyb Granules, Roche). The DIG-labelled probe was denatured by adding
40 µL of the ble-probe reaction mixture to 300 µL of ddH2O and incubated at 99˚C for 5
minutes. This solution was then added to 20 mL of DIG hybridization solution to create the
probe solution. The probe solution was then added to the DNA-affixed nylon membrane and
incubated at 53 ˚C overnight. The following day, the membrane was washed, twice, in 2X
SSC, 0.1% SDS at RT. The membrane was further washed, twice, in 0.1X SSC, 0.1% SDS at
68˚C for 15 minutes. For detection, the membrane was washed and blocked using DIG Wash
and Block Buffer set (Roche) according to the manufacturer’s instructions. An anti-DIG-AP
conjugated antibody from a DIG Nucleic Acid Detection Kit (Roche) was used for detection.
2 µL of the antibody solution was added to 20mL detection solution and incubated with the
membrane at RT for 30 minutes. The blot was then immersed in a washing buffer provided
with the kit. CDP-Star ) was used for ization. 10 µL of the CDP-star solution
was incubated on the ne in 1 mL of detection solution, which was covered in a layer
17746603_1 (GHMatters) P107943.NZ 32 04/06/2021
of ‘sheet-protector’ plastic to hold the on to the membrane. Signal was immediately
detected using a ChemiDoc imaging system.
For flasks assays, cells were grown in media for 2 to 3 days. Pellets were washed
twice in media 2 (9 g/L NaCl, 4 g/L MgSO4, 100 mg/L CaCl2, 5 mg/L FeCl3, 20 g/L
SO4, 0.86 g/L KH2PO4, 150 µg/L n B12, 30 µg/L biotin, 6 mg/L thiamine
hydrochloride, 1.5 mg/L cobalt (II) chloride, 3 mg/L manganese chloride) containing no
sugar. Then, Media 2 containing 20 g/L Glucose and 20 g/L Xylose was inoculated to an
OD600 of 0.05 with the washed cells. As shown in Figures 27A, 27B, 27C and 27D, the
expression of the xylose isomerase, xylulose kinase, and either xylose transporters ed in
up to 71% more xylose used and 40% less xylitol produced than the al strain 7-7.
For flasks assays, cells were grown in media for 2 to 3 days. Pellets were washed
twice in saline. Then, media containing 60 g/L xylose instead of glucose was inoculated to an
OD600 of 0.05 with the washed cells. Samples were taken at various time points and the
amount of sugar remaining in the supernatant was ed by HPLC. Figure 28 shows T18
growth in media ning xylose as the main carbon source requires over-expression of
both an isomerase and a kinase. The expression of the transporters in this background did not
significantly increase xylose usage in this media.
Enhanced xylose usage by T18 7-7 and transporter strains was observed in media
containing carbon from ative feed stocks. For flasks assays, cells were grown in media
for 2 to 3 days. Pellets were washed twice in 0.9% saline solution. Media 2 containing 20 g/L
glucose : 50 g/L xylose as a combination of lab grade glucose and glucose and xylose from
an alternative feedstock from forestry, was inoculated to an OD600nm of 0.05 with the
washed cells. Samples were taken at various time points and the amount of sugar remaining
in the supernatant was analyzed by HPLC. As shown in s 29A and 29B, in media
containing sugars from an alternative feedstock, the T18 7-7 strains encoding for transporters
used more xylose than wild-type, or T18 7-7.
17746603_1 (GHMatters) P107943.NZ 33 04/06/2021
Claims (9)
1. A recombinant Thraustochytrium microorganism comprising: a) two or more copies of a nucleic acid sequence encoding xylose isomerase, wherein the nucleic acid ng xylose isomerase is an exogenous nucleic acid; b) two or more copies of a nucleic acid sequence encoding a xylulose kinase; and c) at least one c acid sequence encoding a xylose transporter, wherein the isomerase, kinase and transporter are integrated into the genome of the Thraustochytrium microorganism.
2. The recombinant Thraustochytrium microorganism of claim 1, wherein the nucleic acid sequence encoding the xylulose kinase is an exogenous nucleic acid sequence.
3. The recombinant Thraustochytrium microorganism of claim 1 or 2, wherein the nucleic acid ce encoding the xylose transporter is an exogenous nucleic acid sequence.
4. The recombinant Thraustochytrium microorganism of any one of claims 1-3, wherein the nucleic acid ce encoding the xylose isomerase is a heterologous nucleic acid sequence.
5. The recombinant Thraustochytrium microorganism of claim 4, wherein the heterologous c acid sequence encoding the xylose isomerase comprises SEQ ID NO:2.
6. The inant Thraustochytrium rganism of any one of claims 2-5, wherein the microorganism comprises at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 copies of the nucleic acid ce encoding the xylulose kinase.
7. The recombinant Thraustochytrium microorganism of any one of claims 3-6, wherein the nucleic acid sequence encoding the xylulose kinase is a heterologous nucleic acid sequence.
8. The recombinant Thraustochytrium microorganism of claim 7, wherein the heterologous c acid sequence encoding the xylulose kinase comprises SEQ ID NO:5.
9. The recombinant Thraustochytrium microorganism of any one of claims 3-8, wherein the microorganism comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 copies of the nucleic acid sequence ng the xylose orter. 17746603_1 (GHMatters) P107943.NZ 34
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562191983P | 2015-07-13 | 2015-07-13 | |
US62/191,983 | 2015-07-13 | ||
US201662354444P | 2016-06-24 | 2016-06-24 | |
US62/354,444 | 2016-06-24 | ||
PCT/IB2016/054185 WO2017009790A1 (en) | 2015-07-13 | 2016-07-13 | Enhancing microalgal metabolism of xylose |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ739056A NZ739056A (en) | 2021-06-25 |
NZ739056B2 true NZ739056B2 (en) | 2021-09-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200325465A1 (en) | Enhancing microbial metabolism of c5 organic carbon | |
US9758787B2 (en) | Engineering microorganisms | |
EP2970926B1 (en) | Engineering microorganisms | |
Wang et al. | Genetic modification of the marine‐derived yeast Yarrowia lipolytica with high‐protein content using a GPI‐anchor‐fusion expression system | |
Gientka et al. | Deproteinated potato wastewater as a sustainable nitrogen source in trichosporon domesticum yeast lipids biosynthesis—A concept of valorization of wastewater from starch industry | |
NZ739056B2 (en) | Enhancing microbial metabolism of c5 organic carbon | |
JP6321645B2 (en) | Method for producing 2-deoxy-siro-inosose | |
US20210388312A1 (en) | Adaptation and process optimization of microorganisms for growth in hemicellulosic derived carbohydrates | |
US20240182934A1 (en) | Oil compositions with engineered lipid profiles and methods of producing same | |
AU2017279745A1 (en) | Engineering thraustochytrid microorganisms |